document_id stringlengths 2 11 | passage_offset uint32 0 909k | passage_text stringlengths 3 257k | section_type stringclasses 19
values | passage_type stringclasses 27
values | annotation_ids listlengths 1 4.93k | annotation_texts listlengths 1 4.93k | annotation_offsets listlengths 1 4.93k | annotation_lengths listlengths 1 4.93k | annotation_groundings listlengths 1 4.93k | annotation_types listlengths 1 4.93k |
|---|---|---|---|---|---|---|---|---|---|---|
1990070 | 47 | The 8534 nucleotide sequence of the genome of the carlavirus, potato virus M (PVM), has been determined. The sequence contains six large open reading frames (ORFs) and non-coding regions consisting of 75 nucleotides at the 5' end, 70 nucleotides followed by a poly(A) tail at the 3' end and 38 and 21 nucleotides between... | null | abstract | [
9,
10,
11,
12,
13,
14,
15
] | [
"carlavirus",
"potato virus M",
"PVM",
"poly(A)",
"initiation codon at nucleotide 76",
"PVM coat protein",
"metal"
] | [
97,
109,
125,
307,
439,
743,
840
] | [
10,
14,
3,
7,
33,
16,
5
] | [
"12163",
"12167",
"12167",
"MESH:D011061",
"tmVar:|Allele|INITIATION|76;VariantGroup:0",
null,
"MESH:D008670"
] | [
"Species",
"Species",
"Species",
"Chemical",
"ProteinMutation",
"Gene",
"Chemical"
] |
1990292 | 172 | We isolated clonal sublines of the established mouse marrow stromal cell line, H-1. These clonal sublines underwent differentiation into adipocytes in various degrees. One subline, H-1/A, underwent adipocyte differentiation after confluence, while another subline, H-1/D, did not differentiate. In H-1/A cells, the 4.5- ... | null | abstract | [
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37
] | [
"mouse",
"H-1",
"H-1/A",
"H-1",
"H-1/A",
"colony-stimulating factor 1",
"CSF-1",
"H-1/A",
"CSF-1",
"H-1/D.",
"Cachectin",
"tumor necrosis factor",
"CSF-1",
"H-1/A",
"CSF-1"
] | [
219,
251,
353,
437,
470,
525,
554,
684,
724,
860,
938,
948,
1008,
1051,
1107
] | [
5,
3,
5,
3,
5,
27,
5,
5,
5,
6,
9,
21,
5,
5,
5
] | [
"10090",
"CVCL:HA53",
"tmVar:c|Allele|H,A|-1;VariantGroup:0;OriginalGene:12977;CorrespondingGene:1435;CorrespondingSpecies:10090",
"CVCL:HA53",
"CVCL:HA53",
"12977",
"12977",
"CVCL:HA53",
"12977",
"CVCL:B4ZW",
"21926",
"21926",
"12977",
"CVCL:HA53",
"12977"
] | [
"Species",
"CellLine",
"DNAMutation",
"CellLine",
"CellLine",
"Gene",
"Gene",
"CellLine",
"Gene",
"CellLine",
"Gene",
"Gene",
"Gene",
"CellLine",
"Gene"
] |
1990431 | 94 | Rhodopsin and the visual pigments are a distinct group within the family of G-protein-linked receptors in that they have a covalently bound ligand, the 11-cis-retinal chromophore, whereas all of the other receptors bind their agonists through noncovalent interactions. The retinal chromophore in rhodopsin is bound by me... | null | abstract | [
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [
"Rhodopsin",
"11-cis-retinal",
"retinal",
"rhodopsin",
"Schiff base",
"rhodopsin",
"K296G",
"K296A",
"Schiff base",
"n-alkylamine",
"11-cis-retinal",
"K296G",
"n-propylamine",
"Schiff base",
"11-cis-retinal"
] | [
94,
246,
367,
390,
434,
497,
538,
548,
731,
749,
766,
819,
833,
847,
862
] | [
9,
14,
7,
9,
11,
9,
5,
5,
11,
12,
14,
5,
13,
11,
14
] | [
"6010",
"MESH:D012172",
"MESH:D012172",
"6010",
"MESH:D012545",
"6010",
"tmVar:p|SUB|K|296|G;HGVS:p.K296G;VariantGroup:0;CorrespondingGene:6010;CorrespondingSpecies:9606",
"tmVar:p|SUB|K|296|A;HGVS:p.K296A;VariantGroup:0;CorrespondingGene:6010;CorrespondingSpecies:9606",
"MESH:D012545",
"-",
"ME... | [
"Gene",
"Chemical",
"Chemical",
"Gene",
"Chemical",
"Gene",
"ProteinMutation",
"ProteinMutation",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Chemical",
"Chemical",
"Chemical"
] |
38363132 | 2,991 | Unfortunately, the emergence and spread of artemisinin resistance in P. falciparum and the declining efficacy of ACTs, first reported in the Greater Mekong sub-region in 2009 and more recently in Papua New Guinea, Guyana, and sub-Saharan Africa (Rwanda, Uganda, Ethiopia, and Eritrea), are a major concern. A better unde... | INTRO | paragraph | [
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54,
55,
56,
57,
58,
59,
60
] | [
"kelch",
"Pfkelch13",
"Pfkelch13",
"Pfkelch13",
"kelch13",
"hemoglobin",
"hemoglobin",
"ART-R",
"ART-R",
"ART-R",
"artemisinin",
"artemisinin",
"dihydroartemisinin",
"DHA",
"ARTs",
"Fe2+",
"heme",
"ART",
"sugars",
"amino acids",
"lipids",
"ART",
"C580Y",
"P. falciparum"... | [
3995,
4007,
4094,
4238,
4288,
4359,
4506,
3478,
3654,
4039,
3034,
3600,
3785,
3805,
3855,
4579,
4584,
4611,
4972,
4980,
4993,
5085,
4203,
3060,
3981,
4651
] | [
5,
9,
9,
9,
7,
10,
10,
5,
5,
5,
11,
11,
18,
3,
4,
4,
4,
3,
6,
11,
6,
3,
5,
13,
13,
13
] | [
"11275",
null,
null,
null,
null,
null,
null,
"MESH:C580424",
"MESH:C580424",
"MESH:C580424",
"MESH:C031327",
"MESH:C031327",
"MESH:C039060",
"MESH:C039060",
"-",
"-",
"MESH:D006418",
"-",
"MESH:D000073893",
"MESH:D000596",
"MESH:D008055",
"-",
"tmVar:p|SUB|C|580|Y;HGVS:p.... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Species",
"Spec... |
38363132 | 5,159 | Here, we investigated whether the early ring parasites can sense a stressful environment and induce a fraction of the parasites to undergo a temporary growth arrest that can survive DHA exposure. Using the NF54WT, 3D7WT, 3D7C580Y, and Cambodian P. falciparum kelch13 wild-type (WT) and mutant (C580Y) parasite lines, we ... | INTRO | paragraph | [
61,
62,
63,
64,
65,
66,
67,
68,
69,
70,
71,
72,
73,
74
] | [
"Pfkech13",
"Pfkelch13",
"Pfkelch13",
"DHA",
"chloroquine",
"CQ",
"DHA",
"DHA",
"DHA",
"artemisinin",
"C580Y",
"P. falciparum kelch13",
"P. falciparum",
"P. falciparum"
] | [
5794,
6691,
6730,
5341,
5522,
5535,
6002,
6041,
6415,
6762,
5453,
5404,
5639,
6456
] | [
8,
9,
9,
3,
11,
2,
3,
3,
3,
11,
5,
21,
13,
13
] | [
null,
null,
null,
"MESH:C039060",
"MESH:D002738",
"MESH:D002738",
"MESH:C039060",
"MESH:C039060",
"MESH:C039060",
"MESH:C031327",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
null,
"5833",
"5833"
] | [
"Gene",
"Gene",
"Gene",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Species",
"Species",
"Species"
] |
38363132 | 8,126 | We observed that ring-stage parasites exposed to complete RPMI medium (control) had a normal, but heterogeneous, intraerythrocytic developmental cycle progression from ring to trophozoite stages at H24 (i.e., average 24% for ring stages and 76% for trophozoite stages) and from trophozoite stages to schizonts at H48 (i.... | RESULTS | paragraph | [
103,
104,
105,
106,
107,
108,
109,
110,
111,
112,
113
] | [
"RPMI medium",
"CQ-R",
"M_NF54_CQ20h",
"M_NF54_CQ20h",
"RPMI",
"M_NF54_CQ20h",
"C580Y",
"C580Y",
"P. falciparum",
"Pfkelch13",
"Pfkelch13"
] | [
8184,
8580,
8629,
9077,
9094,
9330,
9516,
9439,
8585,
9182,
9260
] | [
11,
4,
12,
12,
4,
12,
5,
5,
13,
9,
9
] | [
"-",
"-",
"-",
"-",
"-",
"-",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"5833",
null,
null
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Species",
"Species",
"Species"
] |
38363132 | 11,090 | We next investigated whether the in vitro DHA susceptibility of P. falciparum parasite lines, as expressed by the ring-stage survival assay (RSA0-3h), is affected by the delayed growth progression induced by M_NF54_CQ20h treatment. Early 0-3 hpi ring-stage parasites of 3D7C580Yand the parasite lines PL1C580Y and PL2C58... | RESULTS | paragraph | [
126,
127,
128,
129,
130,
131,
132,
133,
134,
135,
136,
137,
138,
139,
140,
141,
142,
143
] | [
"DHA",
"M_NF54",
"CQ20h",
"RPMI",
"M_NF54",
"CQ20h",
"M_NF54",
"CQ20h",
"CQ",
"DHA",
"dimethylsulfoxide",
"DMSO",
"RPMI",
"RPMI",
"DHA",
"DMSO",
"C580Y",
"P. falciparum"
] | [
11132,
11298,
11305,
11493,
11531,
11538,
11585,
11660,
11729,
11823,
11835,
11854,
11931,
12018,
12166,
12173,
11774,
11154
] | [
3,
6,
5,
4,
6,
5,
6,
5,
2,
3,
17,
4,
4,
4,
3,
4,
5,
13
] | [
"MESH:C039060",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"MESH:D002738",
"MESH:C039060",
"MESH:D004121",
"MESH:D004121",
"-",
"-",
"MESH:C039060",
"MESH:D004121",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"5833"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Species"
] |
38363132 | 12,270 | We found that the proportions of viable parasites of the parasite lines treated with complete RPMI medium were 10.6%, 17.3%, and 18.3% for 3D7C580Y, PL1C580Y, and PL2C580Y, respectively (Fig. 2). Similar proportions of viable parasites were found for parasite lines treated with culture medium prepared from asynchronous... | RESULTS | paragraph | [
144,
145,
146,
147,
148,
149,
150,
151,
152,
153,
154,
155,
156,
157,
158,
159,
160,
161,
162,
163
] | [
"RPMI medium",
"CQ",
"CQ20h",
"CQ",
"CQ20h",
"DHA",
"4-aminoquinoline",
"heme",
"M_NF54_CQ20h medium",
"RPMI medium",
"CQ",
"CQ-R",
"DHA",
"C580Y",
"C580Y",
"C580Y",
"C580Y",
"C580Y",
"C580Y",
"C580Y"
] | [
12364,
12803,
12822,
12994,
13004,
13095,
13142,
13238,
13570,
13690,
13892,
13977,
14069,
13838,
13795,
13766,
12908,
12876,
12847,
12690
] | [
11,
2,
5,
2,
5,
3,
16,
4,
19,
11,
2,
4,
3,
5,
5,
5,
5,
5,
5,
5
] | [
"-",
"MESH:D002738",
"-",
"MESH:D002738",
"-",
"MESH:C039060",
"MESH:C001920",
"MESH:D006418",
"-",
"-",
"MESH:D002738",
"-",
"MESH:C039060",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGrou... | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Protein... |
38363132 | 14,074 | In vitro susceptibility to DHA is reduced in early ring-stage parasites (0-3 hpi) exposed to stress-induced medium. The graphs show the proportion of viable parasites (%) as measured by the RSA0-3h for the parasite lines 3D7C580Y, PL1C580Y, and PL2C580Y in the four environmental conditions: 30 min 0-3 hpi ring stages p... | FIG | fig_caption | [
164,
165,
166,
167,
168,
169,
170,
171,
172,
173,
174,
175,
176,
177
] | [
"DHA",
"RPMI medium",
"RPMI",
"CQ",
"CQ",
"CQ20h",
"CQ",
"CQ20h",
"CQ20h",
"RPMI",
"CQ20h",
"RPMI",
"C580Y",
"C580Y"
] | [
14101,
14421,
14434,
14491,
14528,
14548,
14690,
14709,
14908,
14918,
14990,
15067,
15188,
15154
] | [
3,
11,
4,
2,
2,
5,
2,
5,
5,
4,
5,
4,
5,
5
] | [
"MESH:C039060",
"-",
"-",
"MESH:D002738",
"MESH:D002738",
"-",
"MESH:D002738",
"-",
"-",
"-",
"-",
"-",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;Correspondin... | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation"
] |
38363132 | 15,348 | To confirm whether a signal released by CQ-killed parasites in the culture medium could affect the growth of CQ-R ring-stage parasite lines, we treated 0-3 hpi ring-stage 3D7C580Y, PL1C580Y, and PL2C580Y parasites with dilutions of the M_NF54_CQ20h medium (1/2 and 1/4 dilutions) before assessing their in vitro suscepti... | RESULTS | paragraph | [
180,
181,
182,
183,
184,
185,
186
] | [
"CQ",
"CQ-R",
"M_NF54_CQ20h medium",
"DHA",
"RPMI medium",
"M_NF54_CQ20h medium",
"C580Y"
] | [
15388,
15457,
15584,
15678,
15711,
15736,
15546
] | [
2,
4,
19,
3,
11,
19,
5
] | [
"MESH:D002738",
"-",
"-",
"MESH:C039060",
"-",
"-",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation"
] |
38363132 | 15,860 | As previously observed, we confirmed that the proportions of viable parasites of the parasite lines treated with the M_NF54_CQ20h medium were significantly increased compared to the tested parasite lines exposed to complete RPMI medium. We observed that the parasite survival changed from 10.7% to 29.2%, P = 0.002 for 3... | RESULTS | paragraph | [
187,
188,
189,
190,
191,
192,
193,
194,
195,
196,
197
] | [
"M_NF54",
"CQ20h",
"RPMI medium",
"M_NF54",
"CQ20h",
"M_NF54",
"CQ20h",
"CQ",
"DHA",
"C580Y",
"C580Y"
] | [
15977,
15984,
16084,
16421,
16428,
16465,
16472,
16530,
16639,
16266,
16216
] | [
6,
5,
11,
6,
5,
6,
5,
2,
3,
5,
5
] | [
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"MESH:D002738",
"MESH:C039060",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation"
] |
38363132 | 16,773 | In vitro susceptibility of P. falciparum parasite lines to DHA is restored by dilutions of stress-induced medium. The graphs show the proportion of viable parasites (%) as expressed by the RSA0-3h for the parasite lines 3D7C580Y, PL1C580Y, and PL2C580Y in the four experimental conditions: 30 min 0-3 hpi ring stages pre... | FIG | fig_caption | [
198,
199,
200,
201,
202,
203,
204,
205,
206,
207,
208,
209,
210,
211,
212,
213,
214
] | [
"DHA",
"RPMI medium",
"M_NF54",
"CQ20h",
"M_NF54",
"CQ20h",
"RPMI medium",
"M_NF54",
"CQ20h",
"RPMI medium",
"M_NF54",
"CQ20h",
"M_NF54",
"CQ20h",
"C580Y",
"C580Y",
"P. falciparum"
] | [
16832,
17116,
17153,
17160,
17190,
17197,
17222,
17255,
17262,
17287,
17497,
17504,
17564,
17571,
17750,
17716,
16800
] | [
3,
11,
6,
5,
6,
5,
11,
6,
5,
11,
6,
5,
6,
5,
5,
5,
13
] | [
"MESH:C039060",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"... | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Species"
] |
38363132 | 34,676 | P. falciparum asexual blood-stage parasites were propagated in T50 flasks (Falcon) at 4% hematocrit and parasitemia <1% in 10 mL RPMI-1640 medium (Gibco) supplemented with 10% Albumax (Gibco), 0.2 mM hypoxanthine, 2% AB human serum (heat-inactivated at 56 C), and 4 microg/mL gentamicin (complete RPMI medium). Parasites... | METHODS | paragraph | [
348,
349,
350,
351,
352,
353,
354,
355,
356,
357,
358,
359,
360,
361,
362,
363,
364,
365,
366,
367,
368,
369,
370,
371
] | [
"Pfkelch13",
"Pfkelch13",
"chloroquine resistance transporter",
"pfcrt",
"multidrug-resistant protein",
"pfmdr-1",
"kelch",
"Pfkelch13",
"RPMI-1640 medium",
"Albumax",
"hypoxanthine",
"gentamicin",
"RPMI medium",
"N2",
"O2",
"CO2",
"C580Y",
"580Y",
"P. falciparum",
"human",
"... | [
35395,
35446,
35539,
35580,
35614,
35648,
35688,
35725,
34805,
34852,
34876,
34952,
34973,
35028,
35035,
35046,
35384,
35405,
34676,
34896,
35055,
35525,
35592,
35666
] | [
9,
9,
34,
5,
27,
7,
5,
9,
16,
7,
12,
10,
11,
2,
2,
3,
5,
4,
13,
5,
5,
13,
21,
21
] | [
null,
null,
null,
null,
null,
null,
"11275",
null,
"-",
"-",
"MESH:D019271",
"MESH:D005839",
"-",
"MESH:D009584",
"-",
"MESH:D002245",
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606",
"tmVar:p|Allele|Y|580;VariantGroup:0;Correspon... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Species",
"Species",
"Species",
"Species",
"Species",
"Species"
] |
38363132 | 40,476 | Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance | REF | ref | [
418
] | [
"C580Y"
] | [
40533
] | [
5
] | [
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606"
] | [
"ProteinMutation"
] |
38363132 | 40,664 | Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea | REF | ref | [
419
] | [
"C580Y"
] | [
40734
] | [
5
] | [
"tmVar:p|SUB|C|580|Y;HGVS:p.C580Y;VariantGroup:0;CorrespondingGene:11275;CorrespondingSpecies:9606"
] | [
"ProteinMutation"
] |
38363132 | 41,046 | Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda | REF | ref | [
420
] | [
"R561H"
] | [
41141
] | [
5
] | [
"tmVar:p|SUB|R|561|H;HGVS:p.R561H;VariantGroup:1;CorrespondingGene:11275;CorrespondingSpecies:9606"
] | [
"ProteinMutation"
] |
39872575 | 16,448 | Absence of V599E BRAF mutations in desmoplastic melanomas | REF | ref | [
139,
140
] | [
"BRAF",
"V599E"
] | [
16465,
16459
] | [
4,
5
] | [
"673",
"tmVar:p|SUB|V|599|E;HGVS:p.V599E;VariantGroup:0;CorrespondingGene:673;CorrespondingSpecies:9606"
] | [
"Gene",
"ProteinMutation"
] |
38931793 | 23,550 | Figure 5a,b depict the methodology and setup of the study. The experiment used a stainless-steel water pipeline with an outer diameter of 114.4 mm and a thickness of 6 mm to simulate pipeline leakages. R15I-AST sensors from Mistras Group, Inc. (New Jersey, NJ, USA) were fixed on the pipeline to detect AE signals, which... | METHODS | paragraph | [
31,
32,
33,
34,
35
] | [
"leaks",
"stainless-steel",
"water",
"Water",
"R15I"
] | [
24027,
23631,
23647,
24196,
23752
] | [
5,
15,
5,
5,
4
] | [
"MESH:D019559",
"MESH:D013193",
"MESH:D014867",
"MESH:D014867",
"tmVar:p|SUB|R|15|I;HGVS:p.R15I;VariantGroup:0"
] | [
"Disease",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation"
] |
38931793 | 27,211 | This study utilizes the HSU-Nielsen test as an active AE source to evaluate the attenuation characteristics of the AE sensor. The HSU-Nielsen test involves conducting a pencil lead break test, where a 0.5 mm diameter lead is applied to the pipeline's surface to generate an acoustic emission event. The AE signals detect... | METHODS | paragraph | [
40
] | [
"R15I"
] | [
27872
] | [
4
] | [
"tmVar:p|SUB|R|15|I;HGVS:p.R15I;VariantGroup:0"
] | [
"ProteinMutation"
] |
37274236 | 102 | Kaposiform hemangioendothelioma (KHE) is an extremely rare, locally aggressive vascular neoplasm. The etiopathogenesis of KHE is still poorly understood. In the present study, we found a new mutation in KHE (c.685delA, p.Thr229fs). The KHE patient with the PIK3CA mutation showed complete regression after sirolimus trea... | ABSTRACT | abstract | [
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [
"PIK3CA",
"PIK3CA",
"Kaposiform hemangioendothelioma",
"KHE",
"vascular neoplasm",
"KHE",
"KHE",
"KHE",
"KHE",
"sirolimus",
"sirolimus",
"c.685delA",
"p.Thr229fs",
"patient"
] | [
359,
465,
102,
135,
181,
224,
305,
338,
484,
408,
524,
310,
321,
342
] | [
6,
6,
31,
3,
17,
3,
3,
3,
3,
9,
9,
9,
10,
7
] | [
"5290",
"5290",
"MESH:C537007",
"MESH:C537007",
"MESH:D019043",
"MESH:C537007",
"MESH:C537007",
"MESH:C537007",
"MESH:C537007",
"MESH:D020123",
"MESH:D020123",
"tmVar:c|DEL|685|A;HGVS:c.685delA;VariantGroup:3;CorrespondingGene:5290;CorrespondingSpecies:9606",
"tmVar:p|FS|T|229||;HGVS:p.T229f... | [
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"DNAMutation",
"ProteinMutation",
"Species"
] |
37274236 | 548 | Kaposiform hemangioendothelioma (KHE) is an extremely rare, locally aggressive vascular neoplasm resulting from abnormal angiogenesis and lymphangiogenesis during infancy or early childhood. It is commonly complicated by the occurrence of the Kasabach-Merritt phenomenon, which is characterized by the association of a r... | INTRO | paragraph | [
17,
18,
19,
20,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41
] | [
"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha",
"PIK3CA",
"PIK3CA",
"PIK3CA",
"Kaposiform hemangioendothelioma",
"KHE",
"vascular neoplasm",
"vascular tumor",
"thrombocytopenia",
"coagulopathy",
"KHE",
"KHE",
"PIK3CA-related overgrowth spectrum",
"PROS",
"PROS",... | [
1004,
1076,
1310,
1366,
548,
581,
627,
883,
899,
932,
993,
1138,
1162,
1198,
1205,
1249,
1385,
1447,
1466,
1094,
1106,
1390,
1401,
980
] | [
70,
6,
6,
6,
31,
3,
17,
14,
16,
12,
3,
3,
34,
4,
4,
23,
3,
3,
4,
10,
11,
9,
10,
7
] | [
"5290",
"5290",
"5290",
"5290",
"MESH:C537007",
"MESH:C537007",
"MESH:D019043",
"MESH:D009369",
"MESH:D013921",
"MESH:D001778",
"MESH:C537007",
"MESH:C537007",
"MESH:C537340",
"MESH:C537340",
"MESH:C537340",
"MESH:D002658",
"MESH:C537007",
"MESH:C537007",
"MESH:C537340",
"tmVar... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"DNAMutation",
"ProteinMutation",
"DNAMutation",
"ProteinMutation",
"Spec... |
37274236 | 3,179 | The patient underwent biopsy that confirmed the pathological diagnosis of KHE. Hematoxylin and eosin staining showed typical glomeruloid areas with spindle shaped cells. Immunohistochemical staining was positive for D2-40, PROX-1, LYVE-1, CD31 and CD34 ( Figure 3 ). We also detected the extracted DNA in tumor tissue sa... | CASE | paragraph | [
55,
56,
57,
58,
59,
60,
61,
62,
63,
64,
65,
66
] | [
"PROX-1",
"LYVE-1",
"CD31",
"CD34",
"PIK3CA",
"KHE",
"tumor",
"vascular diseases",
"c.685delA",
"p.Thr229fs",
"patient",
"patient"
] | [
3402,
3410,
3418,
3427,
3723,
3253,
3484,
3669,
3758,
3772,
3183,
3706
] | [
6,
6,
4,
4,
6,
3,
5,
17,
9,
10,
7,
7
] | [
"5629",
"10894",
"5175",
"947",
"5290",
"MESH:C537007",
"MESH:D009369",
"MESH:D014652",
"tmVar:c|DEL|685|A;HGVS:c.685delA;VariantGroup:3;CorrespondingGene:5290;CorrespondingSpecies:9606",
"tmVar:p|FS|T|229||;HGVS:p.T229fsX;VariantGroup:2;CorrespondingGene:5290;CorrespondingSpecies:9606",
"9606",... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"DNAMutation",
"ProteinMutation",
"Species",
"Species"
] |
37274236 | 5,429 | A few mutations and genes had been found to be related to the development of KHE. Zhou et al. demonstrated a somatic translocation between chromosomes 13 and 16 at the bands of 13q14 and 16p13.3 in 10% of cells with KHE nodules; normal cells were also present in the karyotype. Lim et al. identified a single heterozygou... | DISCUSS | paragraph | [
92,
93,
94,
95,
96,
97,
98,
99,
100,
101,
102,
103,
104,
105,
106,
107,
108,
109,
110,
111,
112,
113,
114,
115,
116,
117,
118,
119,
120,
121,
122,
123,
124,
125
] | [
"GNA14",
"G-protein subunit alpha 14",
"GNA14",
"PIK3CA",
"mammalian target of rapamycin",
"mTOR",
"PIK3CA",
"mTOR",
"mTOR",
"PIK3CA",
"mTOR",
"phosphatase and tensin homolog",
"mTOR",
"PIK3CA",
"PIK3CA",
"mTOR",
"PIK3CA",
"KHE",
"KHE",
"KHE",
"fibro-adipose vascular anomaly"... | [
5815,
5822,
5939,
6140,
6173,
6204,
6396,
6437,
6554,
6675,
6722,
6814,
6879,
6984,
7051,
7101,
7281,
5506,
5645,
5866,
6295,
6629,
6747,
6942,
6343,
6414,
7028,
5788,
5798,
5870,
6281,
6379,
6965,
7239
] | [
5,
26,
5,
6,
29,
4,
6,
4,
4,
6,
4,
30,
4,
6,
6,
4,
6,
3,
3,
3,
30,
19,
3,
3,
9,
9,
9,
8,
11,
8,
8,
8,
7,
9
] | [
"9630",
"9630",
"9630",
"5290",
"2475",
"2475",
"5290",
"2475",
"2475",
"5290",
"2475",
"5728",
"2475",
"5290",
"5290",
"2475",
"5290",
"MESH:C537007",
"MESH:C537007",
"MESH:C537007",
"MESH:D009810",
"MESH:D044148",
"MESH:C537007",
"MESH:C537007",
"MESH:D020123",
"M... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"DNAMutation"... |
37274236 | 7,999 | In conclusion, we have presented a new PIK3CA mutation (c.685delA, p.Thr229fs) in KHE. KHE with this PIK3CA mutation may be correlated with a good response to sirolimus. However, more cases are required to validate our findings. | DISCUSS | paragraph | [
142,
143,
144,
145,
146,
147
] | [
"PIK3CA",
"PIK3CA",
"KHE",
"sirolimus",
"c.685delA",
"p.Thr229fs"
] | [
8038,
8100,
8086,
8158,
8055,
8066
] | [
6,
6,
3,
9,
9,
10
] | [
"5290",
"5290",
"MESH:C537007",
"MESH:D020123",
"tmVar:c|DEL|685|A;HGVS:c.685delA;VariantGroup:3;CorrespondingGene:5290;CorrespondingSpecies:9606",
"tmVar:p|FS|T|229||;HGVS:p.T229fsX;VariantGroup:2;CorrespondingGene:5290;CorrespondingSpecies:9606"
] | [
"Gene",
"Gene",
"Disease",
"Chemical",
"DNAMutation",
"ProteinMutation"
] |
37443729 | 7,244 | Bacterial and baculovirus expression constructs. pCI-skNAC was a generous gift from Dr. Rene St-Arnaud (Genetics Unit, Shriners Hospital, Montreal, QC, Canada). pCI-skNAC(BamHI) was a modified construct of pCI-skNAC with an insertion of BamHI and SalI restriction sites at the 5' of skNAC via QuikChange Site-Directed Mu... | METHODS | paragraph | [
102,
103,
104,
105,
106,
107,
108,
109,
110,
111,
112,
113,
114,
115,
116,
117,
118,
119,
120,
121,
122,
123,
124,
125,
126
] | [
"SMYD1B",
"SMYD1B",
"SMYD1B",
"SMYD1B",
"skNAC",
"skNAC",
"SKNAC",
"SKNAC",
"skNAC",
"SKNAC",
"skNAC",
"skNAC",
"skNAC",
"skNAC",
"skNAC",
"skNAC",
"skNAC",
"skNAC",
"pCI",
"pCI",
"pCI",
"pCI",
"pCI",
"Y234F",
"L1952A"
] | [
7598,
7742,
8015,
8113,
8879,
8829,
8790,
8685,
8647,
8464,
8307,
8221,
8181,
8149,
7527,
7454,
7409,
7297,
7293,
7405,
7450,
8177,
8875,
8023,
8665
] | [
6,
6,
6,
6,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
3,
3,
3,
3,
3,
5,
6
] | [
"569027",
"569027",
"569027",
"569027",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"17938",
"CVCL:UI80",
"CVCL:UI80",
"CVCL:UI80",
"CVCL:UI80",
"CVCL:UI80",
"tmVar:p|SUB|Y|234|F;HGVS:p.Y234F;Varia... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"ProteinMutation",
"ProteinMutation"
] |
37443729 | 18,738 | To determine whether the SET domain was required for skNAC methylation, the catalytically conserved Y234 was replaced with phenylalanine (indicated by the asterisk in Figure 2A). This SET domain mutant failed to methylate skNAC (Figure 2C). This result further indicated that SMYD1 has intrinsic methyltransferase activi... | RESULTS | paragraph | [
300,
301,
302,
303,
304
] | [
"skNAC",
"skNAC",
"SMYD1",
"SMYD1",
"Y234"
] | [
18791,
18960,
19014,
19089,
18838
] | [
5,
5,
5,
5,
4
] | [
"4666",
"4666",
"150572",
"150572",
"tmVar:p|Allele|Y|234;VariantGroup:0;OriginalGene:569027;CorrespondingGene:150572;CorrespondingSpecies:7955"
] | [
"Gene",
"Gene",
"Gene",
"Gene",
"ProteinMutation"
] |
37443729 | 39,459 | The SET domain of SMYD1 and the interaction of SMYD1 and skNAC are required for skNAC methylation. (A) Comparison of the C-terminal regions of the SET domains present in SMYD1 and other HMTases. The highly conserved NHxCxPN and GEELxxxY motifs of SET domains, which are strictly essential for KMTase activity, are shown ... | FIG | fig_caption | [
607,
608,
609,
610,
611,
612,
613,
614,
615,
616,
617,
618,
619,
620,
621,
622,
623,
624,
625,
626,
627,
628,
629,
630,
631,
632,
633,
634,
635
] | [
"SMYD1",
"SMYD1",
"skNAC",
"skNAC",
"SMYD1",
"SMYD1",
"SMYD1",
"SMYD1",
"SMYD1",
"skNAC",
"SMYD1b",
"SMYD1b",
"SMYD1b",
"skNAC",
"SMYD1b",
"skNAC",
"skNAC",
"SMYD1",
"SMYD1b",
"HMTases",
"Cys",
"zinc",
"S",
"293T",
"Y234F",
"L1952A",
"L1952A",
"Y234",
"mouse"
... | [
39477,
39506,
39516,
39539,
39629,
39818,
39966,
40073,
40216,
40239,
40270,
40281,
40299,
40511,
40750,
40775,
40896,
40913,
41006,
39645,
40101,
40137,
40167,
40391,
40313,
41096,
40795,
39856,
39960
] | [
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
6,
6,
6,
5,
6,
5,
5,
5,
6,
7,
3,
4,
1,
4,
5,
6,
6,
4,
5
] | [
"150572",
"150572",
"4666",
"4666",
"150572",
"150572",
"150572",
"150572",
"150572",
"4666",
"569027",
"569027",
"569027",
"4666",
"569027",
"4666",
"4666",
"150572",
"569027",
null,
"MESH:D003545",
"MESH:D015032",
"MESH:D013455",
"CVCL:0063",
"tmVar:p|SUB|Y|234|F;HG... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"CellLine",
"ProteinMutation",
"ProteinMutation",
"ProteinMutatio... |
39772163 | 302 | Dual therapies (DT) combining integrase strand transfer inhibitors (INSTIs) with second-generation non-nucleoside reverse transcriptase inhibitors (2nd-Gen-NNRTIs) offer new possibilities for HIV treatment to improve adherence. However, drug resistance associated mutations (RAMs) to prior antiretrovirals may jeopardize... | ABSTRACT | abstract | [
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39
] | [
"pol",
"ART failure",
"non-nucleoside reverse transcriptase inhibitors",
"2nd",
"Gen",
"NNRTIs",
"2nd",
"Gen",
"NNRTI",
"NNRTIs",
"NNRTIs",
"NNRTIs",
"2nd",
"Gen",
"NNRTIs",
"etravirine",
"doravirine",
"rilpivirine",
"dolutegravir",
"bictegravir",
"cabotegravir",
"elvitegra... | [
803,
1841,
401,
450,
454,
458,
710,
714,
718,
866,
1180,
1248,
1292,
1296,
1300,
1308,
1320,
1335,
1457,
1470,
1494,
1522,
1535,
1630,
1634,
1658,
1671,
1684,
1779,
1783,
1787,
1870,
1228,
1259,
494,
770,
797,
887,
2076
] | [
3,
11,
47,
3,
3,
6,
3,
3,
5,
6,
6,
6,
3,
3,
6,
10,
10,
11,
12,
11,
12,
12,
11,
3,
5,
10,
12,
11,
3,
3,
6,
5,
5,
5,
3,
8,
5,
8,
8
] | [
"155348",
"MESH:D051437",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"-",
"MESH:C451734",
"MESH:C000592662",
"MESH:D000068696",
"MESH:C562325",
"MESH:C000620396",
"MESH:C584914",
"MESH:C509700",
"MESH:D000068898",
"-",
"-",
"MESH:C451734",
"MESH:C... | [
"Gene",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
... |
39772163 | 10,938 | A total of 130 participants were included in this study. Participants were predominantly female (59.2%), and the median (interquartile range IQR) age was 38 (27-46) years. The median (IQR) ART duration was 84 (42-144) months; 52 (40.0%) participants were failing regimens based on 2 NRTIs + 1 NNRTI, 66 (50.8%) based on ... | RESULTS | paragraph | [
154,
155,
156,
157,
158,
159,
160
] | [
"NRTIs",
"NNRTI",
"NRTIs",
"ritonavir-boosted protease inhibitor",
"NRTIs",
"NNRTI",
"1 INSTI"
] | [
11221,
11231,
11260,
11270,
11339,
11425,
11347
] | [
5,
5,
5,
36,
5,
5,
7
] | [
"-",
"-",
"-",
"-",
"-",
"-",
"tmVar:|Allele|INSTI|1;VariantGroup:6;CorrespondingGene:5241;CorrespondingSpecies:9606"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"DNAMutation"
] |
39772163 | 12,337 | Concerning NNRTIs and specifically 2nd-Gen-NNRTIs (i.e., DOR, ETR and RPV), prevailing RAMs were Y181C (32.3%), V179L (13.8%), K101PE (10.7%) and H221Y (6.9%) (Table 2). Drug susceptibility assessment revealed that 58.5% (76/130) of patients had intermediate to high-level resistance to DOR, 56.2% (73/130) to ETR and 61... | RESULTS | paragraph | [
177,
178,
179,
180,
181,
182,
183,
184,
185,
186,
187,
188,
189,
190,
191,
192,
193,
194,
195
] | [
"RAMS",
"NNRTIs",
"NNRTIs",
"DOR",
"ETR",
"RPV",
"DOR",
"ETR",
"RPV",
"NNRTI",
"NNRTI",
"NNRTI",
"NNRTI",
"Y181C",
"V179L",
"H221Y",
"patients",
"patients",
"patients"
] | [
12927,
12348,
12380,
12394,
12399,
12407,
12624,
12647,
12673,
12727,
12782,
12889,
12921,
12434,
12449,
12483,
12570,
12875,
12904
] | [
4,
6,
6,
3,
3,
3,
3,
3,
3,
5,
5,
5,
5,
5,
5,
5,
8,
8,
8
] | [
null,
"-",
"-",
"MESH:C000592662",
"MESH:C451734",
"MESH:D000068696",
"MESH:C000592662",
"MESH:C451734",
"MESH:D000068696",
"-",
"-",
"-",
"-",
"tmVar:p|SUB|Y|181|C;HGVS:p.Y181C;VariantGroup:9;CorrespondingGene:155348;CorrespondingSpecies:11676",
"tmVar:p|SUB|V|179|L;HGVS:p.V179L;Variant... | [
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Species",
"Species",
"Species"
] |
39772163 | 12,992 | Regarding RAMs to INSTI, two (1.54%) participants harboured INSTI-RAMs. Both cases were found in INSTI-exposed patients (2/12 (16.6%)), and no resistance was observed in the INSTI-non-exposed group. Among participants harbouring major RAMs to INSTIs, we found specifically E138K (1/130), G140A (1/130), Q148R (1/130), R2... | RESULTS | paragraph | [
196,
197,
198,
199,
200,
201,
202,
203,
204
] | [
"INSTIs",
"E138K",
"G140A",
"Q148R",
"R263K",
"S147G",
"L74I",
"T97A",
"patients"
] | [
13235,
13265,
13280,
13295,
13310,
13329,
13445,
13428,
13103
] | [
6,
5,
5,
5,
5,
5,
4,
4,
8
] | [
"MESH:D054179",
"tmVar:p|SUB|E|138|K;HGVS:p.E138K;VariantGroup:8;CorrespondingGene:5241;CorrespondingSpecies:9606",
"tmVar:c|SUB|G|140|A;HGVS:c.140G>A;VariantGroup:14;CorrespondingGene:155348;CorrespondingSpecies:11676",
"tmVar:p|SUB|Q|148|R;HGVS:p.Q148R;VariantGroup:11;CorrespondingGene:155348;CorrespondingS... | [
"Disease",
"ProteinMutation",
"DNAMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"DNAMutation",
"Species"
] |
39772163 | 15,282 | In the reverse transcriptase (RT) region of HIV-1 pol, analysis showed a high prevalence of NNRTI-RAMs, including Y181C, Y188C and K101PE, which significantly reduce the efficacy of 2nd-Gen-NNRTIs. This high rate of NNRTI-RAMs can be explained by the fact that about 95% had failed first-generation NNRTIs (EFV and NVP) ... | DISCUSS | paragraph | [
225,
226,
227,
228,
229,
230,
231,
232,
233,
234
] | [
"pol",
"NNRTI",
"NNRTIs",
"NNRTI",
"NNRTIs",
"EFV",
"NVP",
"Y181C",
"Y188C",
"HIV-1"
] | [
15332,
15374,
15472,
15498,
15581,
15589,
15597,
15396,
15403,
15326
] | [
3,
5,
6,
5,
6,
3,
3,
5,
5,
5
] | [
"155348",
"-",
"-",
"-",
"-",
"MESH:C098320",
"MESH:D019829",
"tmVar:p|SUB|Y|181|C;HGVS:p.Y181C;VariantGroup:9;CorrespondingGene:155348;CorrespondingSpecies:11676",
"tmVar:p|SUB|Y|188|C;HGVS:p.Y188C;VariantGroup:15;CorrespondingGene:155348;CorrespondingSpecies:11676",
"11676"
] | [
"Gene",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Species"
] |
39772163 | 15,650 | However, 43.85%, 41.54% and 38.46% of the study population remained susceptible to etravirine, doravirine and rilpivirine, respectively. In fact, the previous reported mutations, although frequent, do not necessarily affect the efficacy of 2nd-Gen-NNRTIs at the same levels. For example, Y181C does not affect DOR. | DISCUSS | paragraph | [
235,
236,
237,
238,
239,
240
] | [
"DOR",
"etravirine",
"doravirine",
"rilpivirine",
"NNRTIs",
"Y181C"
] | [
15960,
15733,
15745,
15760,
15898,
15938
] | [
3,
10,
10,
11,
6,
5
] | [
null,
"MESH:C451734",
"MESH:C000592662",
"MESH:D000068696",
"-",
"tmVar:p|SUB|Y|181|C;HGVS:p.Y181C;VariantGroup:9;CorrespondingGene:155348;CorrespondingSpecies:11676"
] | [
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation"
] |
39772163 | 15,965 | Concerning integrase inhibitors, major INSTI-RAMs, such as R263K, S147G, G140A and Q148R, were very rare (<2%). Our study differs from that of Ndashimye et al. (2020) in Uganda, who observed a higher rate of INSTI-RAMs in 47% of patients. This disparity could be explained by variations in patient selection and inclusio... | DISCUSS | paragraph | [
241,
242,
243,
244,
245,
246,
247,
248,
249,
250,
251,
252,
253,
254,
255,
256,
257,
258,
259,
260,
261
] | [
"HIV infection",
"RAL",
"CAB",
"RPV",
"CAB",
"BIC",
"DTG",
"DTG",
"BIC",
"cabotegravir",
"dolutegravir",
"R263K",
"S147G",
"G140A",
"Q148R",
"L74I",
"L74I",
"patients",
"patient",
"patients",
"patients"
] | [
17113,
16366,
16608,
16614,
16785,
16812,
16820,
16849,
16857,
16939,
17055,
16024,
16031,
16038,
16048,
16626,
16432,
16194,
16255,
16347,
16985
] | [
13,
3,
3,
3,
3,
3,
3,
3,
3,
12,
12,
5,
5,
5,
5,
4,
4,
8,
7,
8,
8
] | [
"MESH:D015658",
"MESH:D000068898",
"MESH:C584914",
"MESH:D000068696",
"MESH:C584914",
"MESH:C000620396",
"MESH:C562325",
"MESH:C562325",
"MESH:C000620396",
"MESH:C584914",
"MESH:C562325",
"tmVar:p|SUB|R|263|K;HGVS:p.R263K;VariantGroup:10;CorrespondingGene:155348;CorrespondingSpecies:11676",
... | [
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"DNAMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Species",
"Species",
"Species",
"S... |
39772163 | 17,143 | Depending on certain factors, this relatively favourable genotypic resistance profile justifies the use of this DT combining INSTIs/2nd-Gen-NNRTIs in the context of virological failure. Overall, the different combinations of INSTIs/2nd-Gen-NNRTIs proved effective, regardless of age, duration of treatment or viral subty... | DISCUSS | paragraph | [
262,
263,
264,
265,
266,
267,
268,
269,
270,
271,
272,
273,
274,
275,
276,
277,
278,
279,
280,
281,
282,
283,
284,
285,
286,
287,
288,
289,
290,
291
] | [
"virological failure",
"virological failure",
"virological failure",
"DT",
"Gen",
"NNRTIs",
"Gen",
"NNRTIs",
"NNRTI",
"EFV",
"NVP",
"DT",
"NNRTI",
"DT",
"EFV",
"NVP",
"NNRTI",
"Gen",
"NNRTIs",
"ETR",
"DOR",
"RPV",
"NNRTIs",
"NNRTIs",
"DT",
"Gen",
"NNRTIs",
"DT",... | [
17308,
17668,
18037,
17255,
17279,
17283,
17379,
17383,
17525,
17547,
17554,
17582,
17591,
17603,
17694,
17698,
17761,
17828,
17832,
17840,
17845,
17850,
17864,
18089,
18144,
18157,
18161,
18277,
17938,
17779
] | [
19,
19,
19,
2,
3,
6,
3,
6,
5,
3,
3,
2,
5,
2,
3,
3,
5,
3,
6,
3,
3,
3,
6,
6,
2,
3,
6,
2,
5,
3
] | [
"MESH:D051437",
"MESH:D051437",
"MESH:D051437",
"-",
"-",
"-",
"-",
"-",
"-",
"MESH:C098320",
"MESH:D019829",
"-",
"-",
"-",
"MESH:C098320",
"MESH:D019829",
"-",
"-",
"-",
"MESH:C451734",
"MESH:C000592662",
"MESH:D000068696",
"-",
"-",
"-",
"-",
"-",
"-",
"tmV... | [
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",... |
39772163 | 26,730 | Lack of Impact of Pre-Existing T97A HIV-1 Integrase Mutation on Integrase Strand Transfer Inhibitor Resistance and Treatment Outcome | REF | ref | [
336
] | [
"T97A"
] | [
26761
] | [
4
] | [
"tmVar:c|SUB|T|97|A;HGVS:c.97T>A;VariantGroup:2;CorrespondingGene:5241;CorrespondingSpecies:9606"
] | [
"DNAMutation"
] |
39772163 | 26,863 | High Prevalence of Integrase Mutation L74I in West African HIV-1 Subtypes Prior to Integrase Inhibitor Treatment | REF | ref | [
337
] | [
"L74I"
] | [
26901
] | [
4
] | [
"tmVar:p|SUB|L|74|I;HGVS:p.L74I;VariantGroup:3;CorrespondingGene:155348;CorrespondingSpecies:11676"
] | [
"ProteinMutation"
] |
39772163 | 30,319 | Drug Class Mutations Prevalence n (%) INSTIs * E138K 1 (0.7) G140A 1 (0.7) Q148R 1 (0.7) R263K 1 (0.7) S147G 1 (0.7) 2nd-Gen-NNRTIs A98G 20 (15.3) E138AGKQ 12 (9.2) G190ASE 23 (17.6) L234I 1 (0.7) L100I 4 (3.0) K101PE 14 (10.7) V179L 18 (13.8) Y181C 42 (32.3) Y188CL 5 (3.8) H221Y 9 (6.9) ... | TABLE | table | [
372,
373,
374,
375,
376,
377,
378,
379,
380,
381,
382,
383
] | [
"R263K",
"L234I",
"V179L",
"H221Y",
"M230L",
"Q148R",
"E138K",
"S147G",
"L100I",
"Y181C",
"G140A",
"A98G"
] | [
30416,
30520,
30571,
30624,
30657,
30400,
30368,
30432,
30536,
30589,
30384,
30463
] | [
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
4
] | [
"tmVar:p|SUB|R|263|K;HGVS:p.R263K;VariantGroup:10;CorrespondingGene:155348;CorrespondingSpecies:11676",
"tmVar:p|SUB|L|234|I;HGVS:p.L234I;VariantGroup:12;CorrespondingGene:5241;CorrespondingSpecies:9606",
"tmVar:p|SUB|V|179|L;HGVS:p.V179L;VariantGroup:13;CorrespondingGene:5241;CorrespondingSpecies:9606",
"tmV... | [
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"DNAMutation",
"DNAMutation"
] |
39258142 | 12,439 | Pre-RT (n = 19) Post-RT (n = 19) 6-month F/U (n = 18) P value* LVEDD/BSA 2.6 +- 0.3 2.6 +- 0.3 2.7 +- 0.2 .818 LV mass index 74.7 +- 13.1 67.0 +- 15.4 68.3 +- 12.3 .213 LA volume index 25.3 +- 5.8 21.4 +- 6.6 22.2 +- 7.3 .200 LVEF (%) .493 Median (IQR) 61 (58.5, 65.5) 62 (59.5, 65) 63 (61, 65) Range ... | TABLE | table | [
51,
52,
53
] | [
"A2C",
"A3C",
"A4C"
] | [
13003,
12909,
12956
] | [
3,
3,
3
] | [
"tmVar:c|SUB|A|2|C;HGVS:c.2A>C;VariantGroup:1;CorrespondingGene:2064;CorrespondingSpecies:9606",
"tmVar:c|SUB|A|3|C;HGVS:c.3A>C;VariantGroup:0;CorrespondingGene:2064;CorrespondingSpecies:9606",
"tmVar:c|SUB|A|4|C;HGVS:c.4A>C;VariantGroup:2;CorrespondingGene:2064;CorrespondingSpecies:9606"
] | [
"DNAMutation",
"DNAMutation",
"DNAMutation"
] |
39258142 | 13,723 | Abbreviations: A2C = apical 2-chamber; A3C = apical 3-chamber; A4C = apical 4-chamber; BSA = body surface area; IQR = interquartile range; LA = left atrial; LV = left ventricular; LVEDD = left ventricular end diastolic diameter; LVEF = Left ventricular ejection fraction; RT = radiation therapy. | TABLE | table_footnote | [
54,
55,
56
] | [
"A3C",
"A4C",
"A2C"
] | [
13762,
13786,
13738
] | [
3,
3,
3
] | [
"tmVar:c|SUB|A|3|C;HGVS:c.3A>C;VariantGroup:0;CorrespondingGene:2064;CorrespondingSpecies:9606",
"tmVar:c|SUB|A|4|C;HGVS:c.4A>C;VariantGroup:2;CorrespondingGene:2064;CorrespondingSpecies:9606",
"tmVar:c|SUB|A|2|C;HGVS:c.2A>C;VariantGroup:1;CorrespondingGene:2064;CorrespondingSpecies:9606"
] | [
"DNAMutation",
"DNAMutation",
"DNAMutation"
] |
40495926 | 29,351 | Mean breadth and depth of coverage when mapping enriched sequences to the Schistosoma mansoni reference genome (V10). | FIG | fig_title_caption | [
115,
116
] | [
"V10",
"Schistosoma mansoni"
] | [
29463,
29425
] | [
3,
19
] | [
"tmVar:p|Allele|V|10;VariantGroup:0",
"6183"
] | [
"ProteinMutation",
"Species"
] |
40495926 | 29,469 | Twelve individual miracidia samples extracted from FTA cards, either washed (green [1-6 vertically]) or unwashed (orange [7-12 vertically]) were sequenced and mapped to the S. mansoni reference genome (V10). Mean breadth of coverage per 25kb bin is plotted for each nuclear chromosome and 2kb bins for mitochondrial chro... | FIG | fig_caption | [
117,
118
] | [
"V10",
"S. mansoni"
] | [
29671,
29642
] | [
3,
10
] | [
"tmVar:p|Allele|V|10;VariantGroup:0",
null
] | [
"ProteinMutation",
"Species"
] |
40034091 | 23,558 | As described previously (Gao et al.; Wang et al.), stereotaxic injections were performed using glass pipettes (Cat# 5-000-1001-X10, Drummond) pulled with a micropipette puller (RRID: SCR_021042; P1000, Sutter, USA) to achieve outer diameters of 30-50 microm. Glass pipettes were polished at the tips (Micro Forge MF-830,... | METHODS | paragraph | [
73,
74
] | [
"EF1a",
"H134R"
] | [
23970,
23985
] | [
4,
5
] | [
"22608",
"tmVar:p|SUB|H|134|R;HGVS:p.H134R;VariantGroup:0;OriginalGene:22608;CorrespondingGene:4904;CorrespondingSpecies:10090"
] | [
"Gene",
"ProteinMutation"
] |
40034091 | 48,442 | To address the inhibitory output from L1INs to deeper layer neurons, we conducted optogenetic activation combined with whole-cell recordings in acute brain slices to examine the inhibitory effects of mPFC L1INs on neurons in Layers 2-6. To specifically activate L1INs in the mPFC, we utilized neuron-derived neurotrophic... | RESULTS | paragraph | [
110,
111,
112,
113,
114,
115,
116,
117,
118,
119
] | [
"neuron-derived neurotrophic factor",
"NDNF",
"EF1a",
"NDNF",
"NDNF",
"NDNF",
"H134R",
"mice",
"mice",
"mice"
] | [
48735,
48771,
48945,
49007,
49061,
49225,
48960,
48795,
49016,
49291
] | [
34,
4,
4,
4,
4,
4,
5,
4,
4,
4
] | [
"68169",
"68169",
"22608",
"68169",
"68169",
"68169",
"tmVar:p|SUB|H|134|R;HGVS:p.H134R;VariantGroup:0;OriginalGene:22608;CorrespondingGene:4904;CorrespondingSpecies:10090",
"10090",
"10090",
"10090"
] | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"ProteinMutation",
"Species",
"Species",
"Species"
] |
40034091 | 52,435 | To validate the optogenetic activation of L1INs, we measured light-evoked (5 ms, 473 nm) responses of mPFC L1INs using whole-cell patch-clamp recordings (Figure 5a-d). All recorded L1INs (seven out of seven cells) reliably initiated action potentials in response to light stimulation. Previous studies have shown that th... | RESULTS | paragraph | [
163
] | [
"H134R"
] | [
53386
] | [
5
] | [
"tmVar:p|SUB|H|134|R;HGVS:p.H134R;VariantGroup:0;OriginalGene:22608;CorrespondingGene:4904;CorrespondingSpecies:10090"
] | [
"ProteinMutation"
] |
37324171 | 41,901 | International A (2016) D2166/D2166M-16 standard test method for unconfined compressive strength of cohesive soil | REF | ref | [
371
] | [
"D2166M"
] | [
41930
] | [
6
] | [
"tmVar:p|SUB|D|2166|M;HGVS:p.D2166M;VariantGroup:0"
] | [
"ProteinMutation"
] |
37728561 | 25,298 | Furthermore, MV altered the abundance of proteins involved in chloroplast protein import in WT and fsd1 mutants, while different proteins were affected in these lines (Fig. 2). In WT, MV altered the abundance of OUTER PLASTID ENVELOPE PROTEIN 16-1 and CHLOROPLAST SIGNAL RECOGNITION PARTICLE 54 kDa SUBUNIT, which were d... | RESULTS | paragraph | [
297,
298,
299,
300,
301,
302,
303,
304,
305,
306,
307,
310,
311,
312,
313,
314,
315,
316,
317,
318
] | [
"fsd1",
"HSP 70-2",
"FSD1",
"fsd1",
"-3",
"CASEIN LYTIC PROTEINASE B3",
"VAR2",
"VAR1",
"CHLOROPLAST SIGNAL RECOGNITION PARTICLE 54",
"OUTER PLASTID ENVELOPE PROTEIN 16-1",
"HSP70",
"CHLOROPLAST",
"MV",
"MV",
"MV",
"MV",
"MV",
"MV",
"CHAPERONIN-60",
"DELTA"
] | [
25397,
25882,
25947,
26067,
26265,
26273,
26438,
26630,
25550,
25510,
26003,
25736,
25311,
25482,
25643,
25767,
26044,
26324,
26195,
26260
] | [
4,
8,
4,
4,
2,
26,
4,
4,
42,
35,
5,
11,
2,
2,
2,
2,
2,
2,
13,
5
] | [
"79187",
"831856",
"79187",
"79187",
"829555",
"831398",
"817646",
"834232",
"830273",
"817439",
"820438",
null,
"MESH:D010269",
"MESH:D010269",
"MESH:D010269",
"MESH:D010269",
"MESH:D010269",
"MESH:D010269",
"CVCL:C917",
"tmVar:|Allele|DELTA|;VariantGroup:0;CorrespondingGene:8... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"CellLine",
"DNAMutation"
] |
37728561 | 44,975 | Remarkably, the abundances of chloroplastic chaperones, such as CASEIN LYTIC PROTEINASE B3, CYCLIN DELTA-3, CHAPERONIN-60 ALPHA, and chloroplastic HSP70, were changed only in fsd1 mutants. CYCLIN DELTA-3 functions downstream of CHAPERONIN-60 in the assembly of chloroplast ATP SYNTHASE COUPLING FACTOR 1. These results s... | DISCUSS | paragraph | [
565,
566,
567,
568,
569,
570,
571,
572
] | [
"CASEIN LYTIC PROTEINASE B3",
"-3",
"HSP70",
"fsd1",
"-3",
"MV",
"DELTA",
"DELTA"
] | [
45039,
45079,
45122,
45150,
45176,
45391,
45171,
45074
] | [
26,
2,
5,
4,
2,
2,
5,
5
] | [
"831398",
"829555",
"820438",
"79187",
"829555",
"MESH:D010269",
"tmVar:|Allele|DELTA|;VariantGroup:0;CorrespondingGene:831398;CorrespondingSpecies:3702",
"tmVar:|Allele|DELTA|;VariantGroup:0;CorrespondingGene:831398;CorrespondingSpecies:3702"
] | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Chemical",
"DNAMutation",
"DNAMutation"
] |
37426241 | 6,960 | The structural behavior of the ZnO@beta-SiC composites as well as pure ZnO and beta-SiC was examined by XRD (Bruker, D8-Discover) in the coupled theta-2theta mode over a 2theta range of 20-80 with Cu-Kalpha radiation (lambda = 0.154 nm). The microstructural study was conducted by TEM using a probe-corrected Jeol (JEM ... | METHODS | paragraph | [
67,
68,
69,
70,
71,
72,
73,
74,
75,
76,
77,
78,
79
] | [
"ZnO@beta-SiC",
"ZnO",
"beta-SiC",
"Cu",
"Al",
"Ar+",
"gold",
"MB",
"ZnO@beta-SiC",
"MB",
"mercury",
"MB",
"A 125 W"
] | [
6991,
7031,
7039,
7158,
7493,
7773,
7984,
8329,
8369,
8481,
8624,
9056,
8600
] | [
12,
3,
8,
2,
2,
3,
4,
2,
12,
2,
7,
2,
7
] | [
"-",
"MESH:D015034",
"-",
"MESH:D003300",
"MESH:D000535",
"MESH:D001128",
"MESH:D006046",
"MESH:D008751",
"-",
"MESH:D008751",
"MESH:D008628",
"MESH:D008751",
"tmVar:p|SUB|A|125|W;HGVS:p.A125W;VariantGroup:0"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation"
] |
39916508 | 5,135 | A loss-of-function mutation (H54R) in the ZnT-2 zinc transporter (SLC30A2) of mammary epithelial cells will result in a reduction in zinc secretion into the tubular lumen and consequently a decrease in zinc concentration in breast milk. Reports in four cases confirm the development of transient zinc deficiency in exclu... | DISCUSS | paragraph | [
46,
47,
48,
49,
50,
51,
52,
53
] | [
"SLC30A2",
"zinc deficiency",
"zinc",
"zinc",
"zinc",
"zinc",
"zinc",
"H54R"
] | [
5201,
5431,
5268,
5337,
5514,
5560,
5582,
5164
] | [
7,
15,
4,
4,
4,
4,
4,
4
] | [
"7780",
"MESH:C564286",
"MESH:D015032",
"MESH:D015032",
"MESH:D015032",
"MESH:D015032",
"MESH:D015032",
"tmVar:p|SUB|H|54|R;HGVS:p.H54R;VariantGroup:0;CorrespondingGene:7780;RS#:587776926(Expired);CorrespondingSpecies:9606;CA#:6481"
] | [
"Gene",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation"
] |
39916508 | 11,294 | A dominant negative heterozygous G87R mutation in the zinc transporter, ZnT-2 (SLC30A2), results in transient neonatal zinc deficiency | REF | ref | [
133,
134
] | [
"SLC30A2",
"G87R"
] | [
11373,
11327
] | [
7,
4
] | [
"7780",
"tmVar:p|SUB|G|87|R;HGVS:p.G87R;VariantGroup:1;CorrespondingGene:7780;RS#:185398527;CorrespondingSpecies:9606;CA#:699349"
] | [
"Gene",
"ProteinMutation"
] |
39833238 | 34,965 | 31. Toraya, H., Yoshimura, M. & Somiya, S. Calibration curve for quantitative analysis of the monoclinic-tetragonal ZrO2 system by X-ray diffraction. J. Am. Ceram. Soc. 67, C-119-C-121 (1984). | REF | ref | [
438
] | [
"C-119-C"
] | [
35138
] | [
7
] | [
"tmVar:c|Allele|C|-119;VariantGroup:0;CorrespondingGene:10313;CorrespondingSpecies:9606"
] | [
"DNAMutation"
] |
40216980 | 17,357 | UV-RIP experiment was performed in TNF-alpha stimulated condition and YEATS2 associated MYC-490 eRNA was checked by RT-PCR in (A) MIAPaCa-2, data are presented as mean +- SD from three independent experiments (n = 3). Statistical significance was determined using an unpaired two-tailed t test: ****P = 0.0001 for Input,... | FIG | fig_caption | [
295,
296,
297,
298,
299,
300,
301,
302,
303,
304,
305,
306,
307,
308,
309,
310,
311,
312,
313,
314,
315,
316,
317,
318,
319,
320,
321,
322,
323,
324,
325,
326,
327,
328,
329,
330,
331,
332,
333,
334,
335,
336,
337
] | [
"TNF-alpha",
"YEATS2",
"MYC",
"YEATS2",
"GAPDH",
"YEATS2",
"YEATS2",
"GAPDH",
"YEATS2",
"cMYC",
"YEATS2",
"cMYC",
"YEATS2",
"GAPDH",
"YEATS2",
"YEATS2",
"TNF-alpha",
"YEATS2",
"GAPDH",
"TNF-alpha",
"MYC",
"MYC",
"MYC",
"IP",
"IP",
"IP",
"tyrosine",
"tyrosine",
... | [
17392,
17427,
17445,
17936,
17952,
18022,
18100,
18150,
18187,
18260,
18461,
18535,
18541,
18599,
18670,
18720,
18732,
18840,
18857,
19045,
19204,
19295,
19729,
17696,
17869,
19917,
18652,
19266,
19487,
17487,
17707,
18056,
18124,
18138,
18753,
1... | [
9,
6,
3,
6,
5,
6,
6,
5,
6,
4,
6,
4,
6,
5,
6,
6,
9,
6,
5,
9,
3,
3,
3,
2,
2,
2,
8,
8,
2,
9,
6,
4,
9,
4,
9,
6,
4,
7,
9,
5,
5,
4,
4
] | [
"7124",
"55689",
"4609",
"55689",
"2597",
"55689",
"55689",
"2597",
"55689",
"4609",
"55689",
"4609",
"55689",
"2597",
"55689",
"55689",
"7124",
"55689",
"2597",
"7124",
"4609",
"4609",
"4609",
"MESH:D007184",
"MESH:D007184",
"MESH:D007184",
"MESH:D014443",
"MES... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Cell... |
40216980 | 21,512 | YEATS2 has 21 Tyr amino acid residues in the whole protein (EV3E,F), out of which 4 Tyr amino acids are within the YEATS domain and one of the Tyr (Y313) residues is in the 1st RNA binding region (EV3E,F). It has already been reported that Tyr phosphorylation of Argonaut2 protein could interfere with miRNA binding duri... | RESULTS | paragraph | [
372,
373,
374,
375,
376,
377,
378,
379,
380,
381,
382,
383,
384,
385,
386,
387,
388,
389,
390,
391,
392,
393,
394,
395,
396,
397,
398,
399,
400,
403,
404,
405,
406,
407,
408,
409,
410,
411,
412,
413,
414,
415,
416
] | [
"YEATS2",
"YEATS2",
"TNF",
"YEATS2",
"TNF",
"YEATS2",
"TNF",
"MYC",
"YEATS2",
"YEATS2",
"MYC",
"TNF",
"MYC",
"TNF",
"TNF",
"MYC",
"inflammatory",
"cancer",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"Tyr",
"tyrosine",
"tyrosine",
"MIAPaCa-2",
... | [
21512,
21943,
21963,
22080,
22100,
22231,
22438,
22455,
22481,
22662,
22684,
22876,
23158,
23194,
23898,
24100,
21839,
22605,
21526,
21596,
21655,
21752,
21914,
22057,
22177,
22326,
22521,
22948,
23023,
21982,
21993,
22004,
22119,
22133,
22562,
2... | [
6,
6,
3,
6,
3,
6,
3,
3,
6,
6,
3,
3,
3,
3,
3,
3,
12,
6,
3,
3,
3,
3,
3,
3,
3,
3,
3,
8,
8,
9,
6,
4,
9,
6,
4,
7,
9,
9,
5,
5,
12,
4,
12
] | [
"55689",
"55689",
"7124",
"55689",
"7124",
"55689",
"7124",
"4609",
"55689",
"55689",
"4609",
"7124",
"4609",
"7124",
"7124",
"4609",
"MESH:D007249",
"MESH:D009369",
"MESH:D014443",
"MESH:D014443",
"MESH:D014443",
"MESH:D014443",
"MESH:D014443",
"MESH:D014443",
"MESH:... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Che... |
40216980 | 32,339 | Reagent/resource Reference or source Identifier or catalog number Experimental models MIAPaCa-2 Kind gift from Dr. Shantibhusan Senapati, BRIC Institute of Life Sciences, Bhubaneswar. N/A AsPC-1 Kind gift from Dr. Shantibhusan Senapati, BRIC Institute of Life Sciences, Bhubaneswar. N/A HPNE ATCC CRL-4023 HCT-... | TABLE | table | [
536,
537,
538,
539,
540,
541,
542,
543,
544,
545,
546,
547,
548,
549,
550,
551,
552,
553,
554,
555,
556,
557,
558,
559,
560,
561,
562,
563,
564,
565,
566,
567,
568,
569,
570,
571,
572,
573,
574,
575,
576
] | [
"ZZZ3",
"GAPDH",
"GAPDH",
"GAPDH",
"IL-1beta",
"IL-1beta",
"EGF",
"BRD4",
"cMYC",
"TNF-alpha",
"Lamin",
"YEATS2",
"beta-Actin",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
"MYC",
... | [
33342,
36079,
36046,
33064,
35772,
35735,
36461,
33269,
33441,
36494,
33160,
33032,
33109,
36220,
36174,
36010,
35975,
35933,
35891,
35849,
35807,
34151,
34112,
34073,
34032,
33986,
33940,
33894,
33848,
33783,
33738,
33688,
33637,
35703,
35668,
3... | [
4,
5,
5,
5,
8,
8,
3,
4,
4,
9,
5,
6,
10,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
3,
4,
4,
6,
5,
6,
6,
6,
6
] | [
"26009",
"2597",
"2597",
"2597",
"3553",
"3553",
"1950",
"23476",
"4609",
"7124",
"4000",
"55689",
"728378",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"4609",
"... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene"... |
40216980 | 52,741 | The cross-linking reaction was subsequently halted by the addition of 125 mM glycine for 5 min. The cells were then rinsed once with phosphate-buffered saline (PBS). | METHODS | paragraph | [
735,
736,
737
] | [
"phosphate-buffered saline",
"PBS",
"glycine for 5"
] | [
52874,
52901,
52818
] | [
25,
3,
13
] | [
"-",
"-",
"tmVar:p|Allele|G|5;VariantGroup:6;CorrespondingGene:4609;CorrespondingSpecies:9606"
] | [
"Chemical",
"Chemical",
"ProteinMutation"
] |
39299780 | 32,359 | Funding: This study was supported by the Taipei Veterans General Hospital (no. V105C-201, V107C-153, V109C-136, V110C-119, V113C-146, VTA106-V1-6-1, VTA107-V1-9-1, VTA109-V1-5-1); and the Ministry of Science and Technology, Taiwan (MOST 104-2314-B-075-040, MOST 111-2221-E-075-006). The funding sources did not have any ... | CONCL | footnote | [
261,
262,
263,
264,
265
] | [
"V105C",
"V107C",
"V109C",
"V110C",
"V113C"
] | [
32438,
32449,
32460,
32471,
32482
] | [
5,
5,
5,
5,
5
] | [
"tmVar:p|SUB|V|105|C;HGVS:p.V105C;VariantGroup:2",
"tmVar:p|SUB|V|107|C;HGVS:p.V107C;VariantGroup:1",
"tmVar:p|SUB|V|109|C;HGVS:p.V109C;VariantGroup:0",
"tmVar:p|SUB|V|110|C;HGVS:p.V110C;VariantGroup:4",
"tmVar:p|SUB|V|113|C;HGVS:p.V113C;VariantGroup:3"
] | [
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation"
] |
40002883 | 4,705 | Tyrosine Kinase Inhibitor Therapeutic Target Reference Gefitinib EGFR (Exon 19 deletions, L858R mutations) Erlotinib EGFR (Exon 19 deletions, L858R mutations) Afatinib EGFR (Exon 19 deletions, L858R mutations, uncommon mutations like G719X, L861Q, S768I) Osimertinib EGFR (Exon 19 deletions, L858R mutations, ... | TABLE | table | [
65,
66,
67,
68,
69,
70,
71,
72,
73,
74,
75,
76,
77,
78,
79,
80,
81,
82,
83,
84,
85,
86,
87,
88,
89,
90,
91,
92,
93,
94,
95,
96,
97,
98,
99,
100,
101
] | [
"Tyrosine Kinase",
"RET",
"RET",
"ALK",
"ALK",
"ALK",
"ALK",
"ALK",
"ROS1",
"ROS1",
"ROS1",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"BRAF",
"BRAF",
"MET",
"MET",
"MET",
"MET",
"L858R",
"L858R",
"L858R",
"G719X",
"L861Q",
"S768I",
... | [
4705,
5351,
5332,
5211,
5187,
5169,
5145,
5128,
5216,
5192,
5150,
5396,
5370,
5110,
5046,
4983,
4881,
4827,
4772,
5496,
5456,
5376,
5284,
5240,
5222,
5071,
5008,
4906,
4947,
4954,
4961,
4852,
5088,
4797,
5025,
5501,
5461
] | [
15,
3,
3,
3,
3,
3,
3,
3,
4,
4,
4,
4,
4,
4,
4,
4,
4,
4,
4,
4,
4,
3,
3,
3,
3,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5,
5
] | [
"7294",
"5979",
"5979",
"238",
"238",
"238",
"238",
"238",
"19886",
"19886",
"19886",
"1956",
"1956",
"1956",
"1956",
"1956",
"1956",
"1956",
"1956",
"673",
"673",
"79811",
"79811",
"79811",
"79811",
"tmVar:p|SUB|L|858|R;HGVS:p.L858R;VariantGroup:1;OriginalGene:1364... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Pr... |
40002883 | 5,511 | Abbreviations: EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, c-ros oncogene 1; MET, mesenchymal-epithelial transition factor; RET, rearranged during transfection; BRAF, v-Raf murine sarcoma viral oncogene homolog B; V600E, valine-to-glutamate substitution at codon 600. | TABLE | table_footnote | [
102,
103,
104,
105,
106,
107,
108,
109,
110,
111
] | [
"EGFR",
"epidermal growth factor receptor",
"ALK",
"anaplastic lymphoma kinase",
"ROS1",
"MET",
"RET",
"BRAF",
"V600E",
"valine-to-glutamate substitution at codon 600"
] | [
5526,
5532,
5566,
5571,
5599,
5623,
5670,
5707,
5760,
5767
] | [
4,
32,
3,
26,
4,
3,
3,
4,
5,
45
] | [
"13649",
"13649",
"11682",
"11682",
"19886",
"79811",
"19713",
"109880",
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:10090;CA#:123643",
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;Correspondi... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"ProteinMutation",
"ProteinMutation"
] |
40002883 | 5,867 | The emergence of resistance to EGFR TKIs poses a significant challenge in the treatment of EGFR-mutant NSCLC. EGFR mutations play a critical role in the pathogenesis of NSCLC by driving aberrant activation of tyrosine kinase signaling pathways. These mutations lead to the constitutive activation of the receptor's intri... | INTRO | paragraph | [
113,
114,
115,
116,
117,
118,
119,
120,
121,
122,
123,
124,
125,
126,
127,
128
] | [
"EGFR",
"EGFR",
"EGFR",
"AKT",
"STAT3",
"EGFR",
"EGFR",
"TP53",
"MET",
"tyrosine kinase",
"tyrosine kinase",
"NSCLC",
"NSCLC",
"metastasis",
"T790M",
"patients"
] | [
5898,
5958,
5977,
6309,
6314,
6488,
6654,
6956,
6976,
6192,
6076,
5970,
6036,
6476,
6946,
6623
] | [
4,
4,
4,
3,
5,
4,
4,
4,
3,
15,
15,
5,
5,
10,
5,
8
] | [
"1956",
"1956",
"1956",
"207",
"6774",
"1956",
"1956",
"7157",
"79811",
"7294",
"7294",
"MESH:D002289",
"MESH:D002289",
"MESH:D009362",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928",
"9606"... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"ProteinMutation",
"Species"
] |
40002883 | 6,997 | Secondary or acquired resistance typically develops after an initial response to EGFR-TKIs. This type of resistance develops via either on-target or off-target mechanisms. On-target resistance mechanisms include alterations in the target enzyme, typically the TKI-binding tyrosine kinase, which results in a reduction in... | INTRO | paragraph | [
129,
130,
131,
132,
133,
134,
135,
136
] | [
"EGFR",
"tyrosine kinase",
"tyrosine kinase",
"EGFR",
"ATP",
"T790M",
"C797X",
"T790M"
] | [
7078,
7269,
7653,
7814,
7629,
7582,
7552,
7543
] | [
4,
15,
15,
4,
3,
5,
5,
5
] | [
"1956",
"7294",
"7294",
"1956",
"MESH:D000255",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928",
"tmVar:p|SUB|C|797|X;HGVS:p.C797X;VariantGroup:3;CorrespondingGene:1956;CorrespondingSpecies:9606",
"tmVar:p|S... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation"
] |
40002883 | 8,559 | C797X mutation | METHODS | paragraph | [
145
] | [
"C797X"
] | [
8559
] | [
5
] | [
"tmVar:p|SUB|C|797|X;HGVS:p.C797X;VariantGroup:3;CorrespondingGene:1956;CorrespondingSpecies:9606"
] | [
"ProteinMutation"
] |
40002883 | 9,017 | Upon progression on osimertinib, approximately 15% of tumors develop on-target mutations, with EGFR C797X in exon 20 being the most prevalent. This mutation hampers the covalent binding of osimertinib to the EGFR kinase domain. Other notable acquired mutations include L718Q/V, G719A, and G724S in exon 18. Fourth-genera... | METHODS | paragraph | [
150,
151,
152,
153,
154,
155,
156,
157,
158,
159,
160,
161,
162,
163,
164,
165,
166,
167,
168,
169,
170,
171,
172,
173,
174,
175,
176,
177,
178
] | [
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"tumors",
"NSCLC",
"cancer",
"NSCLC",
"NSCLC",
"osimertinib",
"osimertinib",
"BLU-94573",
"BBT-17674",
"BLU-945",
"osimertinib",
"JIN",
"BDTX-1535",
"C797X",
"L718Q/V",
"G719A",
"G724S",
"C797S",
"C797S",
"T7... | [
9112,
9225,
9342,
9477,
9698,
9812,
10067,
9071,
9489,
9597,
9909,
10079,
9037,
9206,
9357,
9371,
9465,
9649,
9783,
9990,
9117,
9286,
9295,
9306,
9929,
9628,
9942,
9915,
10030
] | [
4,
4,
4,
4,
4,
4,
4,
6,
5,
6,
5,
5,
11,
11,
9,
9,
7,
11,
3,
9,
5,
7,
5,
5,
5,
5,
5,
8,
8
] | [
"1956",
"1956",
"1956",
"1956",
"1956",
"1956",
"1956",
"MESH:D009369",
"MESH:D002289",
"MESH:D009369",
"MESH:D002289",
"MESH:D002289",
"MESH:C000596361",
"MESH:C000596361",
"-",
"-",
"-",
"MESH:C000596361",
"-",
"-",
"tmVar:p|SUB|C|797|X;HGVS:p.C797X;VariantGroup:3;Correspon... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Prote... |
40002883 | 14,456 | RET fusions are also reported as acquired resistance mechanism after EGFR TKI treatment. When compared to primary RET fusions, the proportion of CCDC6-RET in patients with acquired resistance to EGFR TKIs was higher. Additionally, RET fusions were more frequently linked to acquired resistance to third-generation EGFR-T... | METHODS | paragraph | [
278,
279,
280,
281,
282,
283,
284,
285,
286,
287,
288,
289,
290,
291,
292,
293,
294,
295,
296,
297,
298,
299,
300,
301
] | [
"RET",
"EGFR",
"RET",
"CCDC6",
"RET",
"EGFR",
"RET",
"EGFR",
"RET",
"BRAF",
"osimertinib",
"osimertinib",
"selpercatinib",
"osimertinib",
"dabrafenib",
"trametinib",
"osimertinib",
"vemurafenib",
"osimertinib",
"osimertinib",
"V600E",
"patients",
"patients",
"patients"
... | [
14456,
14525,
14570,
14601,
14607,
14651,
14687,
14770,
14851,
15118,
14869,
14901,
14917,
15138,
15183,
15198,
15214,
15238,
15255,
15335,
15123,
14614,
14822,
15313
] | [
3,
4,
3,
5,
3,
4,
3,
4,
3,
4,
11,
11,
13,
11,
10,
10,
11,
11,
11,
11,
5,
8,
8,
8
] | [
"5979",
"1956",
"5979",
"8030",
"5979",
"1956",
"5979",
"1956",
"5979",
"673",
"MESH:C000596361",
"MESH:C000596361",
"MESH:C000656166",
"MESH:C000596361",
"MESH:C561627",
"MESH:C560077",
"MESH:C000596361",
"MESH:D000077484",
"MESH:C000596361",
"MESH:C000596361",
"tmVar:p|SUB|... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Species",
"Species",
"Species"
] |
40002883 | 38,001 | In a study on 138 patients with EGFR mutation who underwent re-biopsy after progression following EGFR-TKI failure, the proportion of patients with >=50% PD-L1 expression increased significantly from baseline (14%) to 28%. Similar results have been reported in other studies. Various mechanisms have been suggested for P... | METHODS | paragraph | [
708,
709,
710,
711,
712,
713,
714,
715,
716,
717,
718,
719,
720,
721,
722,
723,
724,
725,
726,
727,
728,
729,
730
] | [
"EGFR",
"EGFR",
"PD-L1",
"PD-L1",
"EGFR",
"HGF",
"c-MET",
"PD-L1",
"PD-L1",
"STAT3",
"PI3K",
"EGFR",
"PD-L1",
"AKT",
"BIM",
"PD-L1",
"EGFR",
"NSCLC",
"NSCLC",
"NSCLC",
"T790M",
"patients",
"patients"
] | [
38033,
38099,
38155,
38320,
38350,
38439,
38444,
38524,
38609,
38690,
38803,
38860,
38884,
38912,
38982,
39054,
39074,
38410,
38533,
39086,
38473,
38019,
38135
] | [
4,
4,
5,
5,
4,
3,
5,
5,
5,
5,
4,
4,
5,
3,
3,
5,
4,
5,
5,
5,
5,
8,
8
] | [
"1956",
"1956",
"29126",
"29126",
"1956",
"3082",
"4233",
"29126",
"29126",
"6774",
"5291",
"1956",
"29126",
"207",
"10018",
"29126",
"1956",
"MESH:D002289",
"MESH:D002289",
"MESH:D002289",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"ProteinMutation",
"Species",
"Species"
] |
40002883 | 40,208 | Recent studies have highlighted the critical role of the adenosine pathway in immune suppression, particularly in regulating lymphocyte activity. Within the TME, adenosine is a key modulator of immune responses. Its accumulation is facilitated by ectonucleotidase CD73, which promotes adenosine production and subsequent... | METHODS | paragraph | [
750,
751,
752,
753,
754,
755,
756,
757,
758
] | [
"CD73",
" receptor",
"CD8",
"CD4",
"tumor",
"adenosine",
"adenosine",
"adenosine",
"A2A"
] | [
40472,
40639,
40700,
40777,
40571,
40265,
40370,
40493,
40636
] | [
4,
9,
3,
3,
5,
9,
9,
9,
3
] | [
"23959",
"135",
"925",
"920",
"MESH:D009369",
"MESH:D000241",
"MESH:D000241",
"MESH:D000241",
"tmVar:c|SUB|A|2|A;HGVS:c.2A>A;VariantGroup:8;CorrespondingGene:925;RS#:1256344587;CorrespondingSpecies:9606"
] | [
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"DNAMutation"
] |
40002883 | 45,351 | Reversal of the M2 phenotype to M1 is effective at overcoming gefitinib resistance. Methionine sulfoxide reductase A (MsrA) helps protect the T790M-mutant EGFR protein. When macrophages switch from the M2 to M1 phenotype, the production of reactive oxygen species (ROS) increases, lowering MsrA levels and accelerating E... | METHODS | paragraph | [
823,
824,
825,
826,
827,
828,
829,
830,
831,
832,
833,
834,
835,
836,
837,
838,
839,
840,
841,
842,
843,
844,
845,
846,
847,
848,
849,
850,
851
] | [
"Methionine sulfoxide reductase A",
"MsrA",
"EGFR",
"MsrA",
"EGFR",
"HER2",
"PD-L1",
"TGF-beta",
"PD-L1",
"NSCLC",
"tumor",
"tumor",
"NSCLC",
"gefitinib",
"reactive oxygen species",
"ROS",
"trastuzumab",
"gefitinib",
"vorinostat",
"Trastuzumab",
"vorinostat",
"gefitinib",
... | [
45435,
45469,
45506,
45641,
45670,
45795,
45932,
46238,
46296,
45809,
45870,
46383,
46425,
45413,
45591,
45616,
45710,
45749,
45763,
45775,
45830,
45972,
45986,
46140,
46248,
46347,
46449,
45493,
46431
] | [
32,
4,
4,
4,
4,
4,
5,
8,
5,
5,
5,
5,
5,
9,
23,
3,
11,
9,
10,
11,
10,
9,
11,
3,
11,
9,
5,
5,
5
] | [
"110265",
"110265",
"13649",
"110265",
"13649",
"13866",
"60533",
"21803",
"60533",
"MESH:D002289",
"MESH:D009369",
"MESH:D009369",
"MESH:D002289",
"MESH:D000077156",
"MESH:D017382",
"MESH:D017382",
"MESH:D000068878",
"MESH:D000077156",
"MESH:D000077337",
"MESH:D000068878",
"... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemi... |
40002883 | 48,474 | The KEYNOTE-789 trial is a randomized, double-blind, phase III study evaluating the efficacy of pembrolizumab in combination with pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, and metastatic non-squamous NSCLC (NCT03515837). Patients with stage IV non-squamous NSCLC, confirmed ... | METHODS | paragraph | [
877,
878,
879,
880,
881,
882,
883,
884,
885,
886,
887,
888,
889,
890,
891,
892,
893,
894,
895,
896,
897,
898,
899,
900,
901,
902,
903
] | [
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"EGFR",
"NSCLC",
"IV",
"NSCLC",
"NSCLC",
"pembrolizumab",
"pemetrexed",
"platinum",
"pembrolizumab",
"pemetrexed",
"carboplatin",
"cisplatin",
"pemetrexed",
"pembrolizumab",
"pembrolizumab",
"pembrolizumab",
"pembrolizumab",
"L858R",
"patie... | [
48679,
48809,
48847,
49878,
49917,
48720,
48761,
48777,
49890,
48570,
48604,
48619,
48895,
48993,
49008,
49023,
49046,
49171,
49416,
49623,
49748,
48803,
48650,
48741,
49092,
49604,
49677
] | [
4,
4,
4,
4,
4,
5,
2,
5,
5,
13,
10,
8,
13,
10,
11,
9,
10,
13,
13,
13,
13,
5,
8,
8,
8,
8,
8
] | [
"1956",
"1956",
"1956",
"1956",
"1956",
"MESH:D002289",
"MESH:D006011",
"MESH:D002289",
"MESH:D002289",
"MESH:C582435",
"MESH:D000068437",
"MESH:D010984",
"MESH:C582435",
"MESH:D000068437",
"MESH:D016190",
"MESH:D002945",
"MESH:D000068437",
"MESH:C582435",
"MESH:C582435",
"MESH... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutation",
"Species",
"Species",
... |
40002883 | 51,992 | Owing to the relatively small number of patients enrolled in studies assessing the efficacy of immunotherapy in patients with EGFR mutations, no definite subgroups that would benefit from immunotherapy have been established. A retrospective study indicated that patients with prior TKI treatment and PFS < 10 months exhi... | METHODS | paragraph | [
935,
936,
937,
938,
939,
940,
941,
942,
943,
944,
945,
946,
947,
948,
949
] | [
"EGFR",
"PD-L1",
"EGFR",
"PD-L1",
"PD-L1",
"pembrolizumab",
"T790M",
"L858R",
"T790M",
"patients",
"patients",
"patients",
"patients",
"patients",
"patients"
] | [
52118,
52361,
52394,
52801,
52893,
52976,
52655,
52589,
52432,
52032,
52104,
52254,
52571,
52879,
53003
] | [
4,
5,
4,
5,
5,
13,
5,
5,
5,
8,
8,
8,
8,
8,
8
] | [
"1956",
"29126",
"1956",
"29126",
"29126",
"MESH:C582435",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928",
"tmVar:p|SUB|L|858|R;HGVS:p.L858R;VariantGroup:1;OriginalGene:13649;CorrespondingGene:1956;RS#:1214... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Species",
"Species",
"Species",
"Species",
"Species",
"Species"
] |
40002883 | 55,706 | These clinical benefits may be associated with the role of VEGFR-2 in TKI resistance. A study by Osude et al. demonstrated that in EGFR-TKI-resistant NSCLC cell lines:specifically those harboring EGFR double mutations (L858R and T790M):the expression of VEGF, VEGFR-2, and its co-receptor neuropilin-1 (NP-1) was signifi... | METHODS | paragraph | [
994,
995,
996,
997,
998,
999,
1000,
1001,
1002,
1003,
1004,
1005,
1006,
1007,
1008,
1009,
1010
] | [
"VEGFR-2",
"EGFR",
"EGFR",
"VEGF",
"VEGFR-2",
"neuropilin-1",
"NP-1",
"VEGFR-2",
"NP-1",
"VEGFR-2",
"EGFR",
"NSCLC",
"NSCLC",
"erlotinib",
"erlotinib",
"L858R",
"T790M"
] | [
55765,
55837,
55902,
55960,
55966,
55995,
56009,
56165,
56177,
56258,
56316,
55856,
56335,
56281,
56376,
55925,
55935
] | [
7,
4,
4,
4,
7,
12,
4,
7,
4,
7,
4,
5,
5,
9,
9,
5,
5
] | [
"3791",
"1956",
"1956",
"7422",
"3791",
"8829",
"8829",
"3791",
"8829",
"3791",
"1956",
"MESH:D002289",
"MESH:D002289",
"MESH:D000069347",
"MESH:D000069347",
"tmVar:p|SUB|L|858|R;HGVS:p.L858R;VariantGroup:1;OriginalGene:13649;CorrespondingGene:1956;RS#:121434568;CorrespondingSpecies:10... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Chemical",
"Chemical",
"ProteinMutation",
"ProteinMutation"
] |
40002883 | 57,200 | The IMpower150 trial showed significant improvements in PFS and OS with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus standard-of-care bevacizumab plus carboplatin plus paclitaxel in chemotherapy-naive patients with non-squamous NSCLC. In the final analysis for the subgroup with EGFR muta... | METHODS | paragraph | [
1025,
1026,
1027,
1028,
1029,
1030,
1031,
1032,
1033,
1034,
1035,
1036,
1037,
1038,
1039,
1040,
1041,
1042,
1043,
1044,
1045,
1046,
1047,
1048,
1049,
1050,
1051,
1052
] | [
"EGFR",
"PD-L1",
"VEGF",
"VEGF",
"EGFR",
"EGFR",
"VEGF",
"EGFR",
"NSCLC",
"NSCLC",
"NSCLC",
"atezolizumab",
"bevacizumab",
"carboplatin",
"paclitaxel",
"ABCP",
"bevacizumab",
"carboplatin",
"paclitaxel",
"ABCP",
"ivonescimab",
"ivonescimab",
"ivonescimab",
"ivonescimab"... | [
57511,
57710,
57720,
57817,
57922,
58631,
58666,
58771,
57460,
57934,
58643,
57272,
57290,
57307,
57324,
57336,
57366,
57383,
57400,
57531,
57765,
57990,
58236,
58525,
58361,
57433,
58503,
58739
] | [
4,
5,
4,
4,
4,
4,
4,
4,
5,
5,
5,
12,
11,
11,
10,
4,
11,
11,
10,
4,
11,
11,
11,
11,
5,
8,
8,
8
] | [
"1956",
"29126",
"7422",
"7422",
"1956",
"1956",
"7422",
"1956",
"MESH:D002289",
"MESH:D002289",
"MESH:D002289",
"MESH:C000594389",
"MESH:D000068258",
"MESH:D016190",
"MESH:D017239",
"-",
"MESH:D000068258",
"MESH:D016190",
"MESH:D017239",
"-",
"-",
"-",
"-",
"-",
"tmV... | [
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"ProteinMutatio... |
40002883 | 69,011 | Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis | REF | ref | [
1129,
1130
] | [
"BRAF",
"V600E"
] | [
69072,
69077
] | [
4,
5
] | [
"673",
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:10090;CA#:123643"
] | [
"Gene",
"ProteinMutation"
] |
40002883 | 69,159 | Encorafenib and Binimetinib: A New Treatment Option for BRAFV600E-Mutant Non-Small-Cell Lung Cancer | REF | ref | [
1131
] | [
"BRAFV600E"
] | [
69215
] | [
9
] | [
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:10090;CA#:123643"
] | [
"ProteinMutation"
] |
40002883 | 69,896 | HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation | REF | ref | [
1139,
1140,
1141,
1142,
1143
] | [
"HER2",
"EGFR",
"EGFR",
"EGFR",
"T790M"
] | [
69896,
70034,
69983,
69964,
70039
] | [
4,
4,
4,
4,
5
] | [
"13866",
"1956",
"1956",
"1956",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"Gene",
"Gene",
"Gene",
"ProteinMutation"
] |
40002883 | 70,589 | Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors | REF | ref | [
1148,
1149,
1150
] | [
"EGFR",
"EGFR",
"G724S"
] | [
70704,
70600,
70605
] | [
4,
4,
5
] | [
"1956",
"1956",
"tmVar:p|SUB|G|724|S;HGVS:p.G724S;VariantGroup:7;OriginalGene:13649;CorrespondingGene:1956;RS#:748011710;CorrespondingSpecies:10090;CA#:4266230"
] | [
"Gene",
"Gene",
"ProteinMutation"
] |
40002883 | 71,109 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | REF | ref | [
1156,
1157,
1158
] | [
"EGFR",
"MET",
"T790M"
] | [
71169,
71109,
71150
] | [
4,
3,
5
] | [
"1956",
"79811",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"Gene",
"ProteinMutation"
] |
40002883 | 71,244 | Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study | REF | ref | [
1159,
1160
] | [
"EGFR",
"T790M"
] | [
71310,
71315
] | [
4,
5
] | [
"1956",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"ProteinMutation"
] |
40002883 | 75,508 | Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance | REF | ref | [
1205,
1206,
1207
] | [
"EGFR",
"BRAF",
"V600E"
] | [
75550,
75569,
75574
] | [
4,
4,
5
] | [
"1956",
"673",
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:10090;CA#:123643"
] | [
"Gene",
"Gene",
"ProteinMutation"
] |
40002883 | 75,672 | Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation | REF | ref | [
1208,
1209
] | [
"BRAF",
"V600E"
] | [
75807,
75812
] | [
4,
5
] | [
"673",
"tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:5;OriginalGene:109880;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:10090;CA#:123643"
] | [
"Gene",
"ProteinMutation"
] |
40002883 | 79,645 | Reprogramming Tumor-Associated Macrophages To Reverse EGFR(T790M) Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat | REF | ref | [
1254,
1255
] | [
"EGFR",
"T790M"
] | [
79699,
79704
] | [
4,
5
] | [
"1956",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"ProteinMutation"
] |
40002883 | 81,674 | Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway | REF | ref | [
1272,
1273,
1274,
1275
] | [
"AKT",
"EGFR",
"PI3K",
"T790M"
] | [
81766,
81729,
81761,
81692
] | [
3,
4,
4,
5
] | [
"207",
"1956",
"5291",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"Gene",
"Gene",
"ProteinMutation"
] |
40002883 | 89,962 | Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M-Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery | REF | ref | [
1362,
1363
] | [
"PD-L1",
"EGFRT790M"
] | [
90075,
90035
] | [
5,
9
] | [
"29126",
"tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;OriginalGene:13649;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:10090;CA#:90928"
] | [
"Gene",
"ProteinMutation"
] |
20338449 | 202 | Johne's disease is a chronic enteritis caused by Mycobacterium avium ssp. paratuberculosis (MAP) that causes substantial financial losses for the cattle industry. Susceptibility to MAP infection is reported to be determined in part by genetic factors, so marker-assisted selection could help to obtain bovine populations... | null | abstract | [
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54,
55,
56,
57,
58,
59,
60,
61,
62,
63,
64,
65,
66,
67
] | [
"Johne's disease",
"enteritis",
"Mycobacterium avium ssp",
"paratuberculosis",
"MAP",
"cattle",
"MAP infection",
"bovine",
"MAP infection",
"Solute carrier family 11 member 1",
"SLC11A1",
"intracellular infections",
"bovine",
"MAP infection",
"SLC11A1",
"MAP infection",
"cattle",
"... | [
202,
231,
251,
276,
294,
348,
383,
504,
558,
573,
608,
749,
809,
816,
949,
1068,
1085,
1192,
1387,
1401,
1507,
1526,
1601,
1630,
1654,
1731,
1765,
1782,
1819
] | [
15,
9,
23,
16,
3,
6,
13,
6,
13,
33,
7,
24,
6,
13,
7,
13,
6,
10,
9,
12,
13,
9,
27,
5,
7,
7,
13,
6,
9
] | [
"MESH:D010283",
"MESH:D004751",
null,
"MESH:D010283",
"MESH:D010283",
"9913",
"MESH:D015270",
"9913",
"MESH:D015270",
"282470",
"282470",
"MESH:D015270",
"9913",
"MESH:D015270",
"282470",
"MESH:D015270",
"9913",
"9913",
"tmVar:c|SUB|C|1067|G;HGVS:c.1067C>G;VariantGroup:0;Original... | [
"Disease",
"Disease",
"Species",
"Disease",
"Disease",
"Species",
"Disease",
"Species",
"Disease",
"Gene",
"Gene",
"Disease",
"Species",
"Disease",
"Gene",
"Disease",
"Species",
"Species",
"DNAMutation",
"DNAMutation",
"Disease",
"DNAMutation",
"ProteinMutation",
"Prote... |
20338454 | 105 | The main goal of the current work was to identify single nucleotide polymorphisms (SNP) that might create or disrupt microRNA (miRNA) target sites in the caprine casein genes. The 3' untranslated regions of the goat alpha(S1)-, alpha(S2)-, beta-, and kappa-casein genes (CSN1S1, CSN1S2, CSN2, and CSN3, respectively) wer... | null | abstract | [
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47
] | [
"caprine",
"goat",
"CSN1S1",
"CSN1S2",
"CSN2",
"CSN3",
"c.175C>T",
"CSN1S1",
"c.109T>C",
"c.139G>C",
"c.160T>C",
"CSN1S2",
"c.216C>T",
"CSN2",
"c.175C>T",
"CSN1S1",
"goats",
"CSN1S1",
"miR-101",
"bovine",
"goats",
"CSN1S1",
"goat"
] | [
259,
316,
376,
384,
392,
402,
581,
593,
601,
611,
625,
637,
649,
661,
978,
992,
1025,
1053,
1130,
1176,
1210,
1248,
1494
] | [
7,
4,
6,
6,
4,
4,
8,
6,
8,
8,
8,
6,
8,
4,
8,
6,
5,
6,
7,
6,
5,
6,
4
] | [
null,
null,
"100750242",
"100750241",
"100860784",
"100861231",
"tmVar:c|SUB|C|175|T;HGVS:c.175C>T;VariantGroup:1;OriginalGene:100750242;CorrespondingGene:1446;CorrespondingSpecies:9925",
"100750242",
"tmVar:c|SUB|T|109|C;HGVS:c.109T>C;VariantGroup:2;OriginalGene:100750242;CorrespondingGene:1446;Cor... | [
"Species",
"Species",
"Gene",
"Gene",
"Gene",
"Gene",
"DNAMutation",
"Gene",
"DNAMutation",
"DNAMutation",
"DNAMutation",
"Gene",
"DNAMutation",
"Gene",
"DNAMutation",
"Gene",
"Species",
"Gene",
"Gene",
"Species",
"Species",
"Gene",
"Species"
] |
20338477 | 80 | PURPOSE: To investigate the influence of demethylation with 5-aza-cytidine (AZA) on radiation sensitivity and to define the intrinsic radiation sensitivity of methylation deficient colorectal carcinoma cells. METHODS AND MATERIALS: Radiation sensitizing effects of AZA were investigated in four colorectal carcinoma cell... | null | abstract | [
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54,
55,
56,
57
] | [
"5-aza-cytidine",
"AZA",
"colorectal carcinoma",
"AZA",
"colorectal carcinoma",
"HCT116",
"SW480",
"L174 T",
"Co115",
"AZA",
"cancer",
"DNMT1",
"DNMT3b",
"AZA",
"(SER) of 1",
"AZA",
"p16",
"hMLH1",
"AZA",
"AZA",
"HCT116",
"DNMT3b",
"SER of 2",
"DNMT3b",
"DNMT1",
"SE... | [
140,
156,
261,
345,
375,
408,
416,
423,
431,
461,
584,
731,
738,
814,
1015,
1071,
1114,
1122,
1211,
1328,
1356,
1370,
1442,
1481,
1488,
1529,
1577,
1658
] | [
14,
3,
20,
3,
20,
6,
5,
6,
5,
3,
6,
5,
6,
3,
10,
3,
3,
5,
3,
3,
6,
6,
8,
6,
5,
8,
3,
20
] | [
"MESH:D001374",
"MESH:D001374",
"MESH:D015179",
"MESH:D001374",
"MESH:D015179",
"CVCL:0291",
"CVCL:0546",
"tmVar:p|SUB|L|174|T;HGVS:p.L174T;VariantGroup:2",
"CVCL:D102",
"MESH:D001374",
"MESH:D009369",
"1786",
"1789",
"MESH:D001374",
"tmVar:p|Allele|S|1;VariantGroup:0;CorrespondingGene:1... | [
"Chemical",
"Chemical",
"Disease",
"Chemical",
"Disease",
"CellLine",
"CellLine",
"ProteinMutation",
"CellLine",
"Chemical",
"Disease",
"Gene",
"Gene",
"Chemical",
"ProteinMutation",
"Chemical",
"Gene",
"Gene",
"Chemical",
"Chemical",
"CellLine",
"Gene",
"ProteinMutation"... |
20338844 | 89 | Expression of the Na(+)/glucose cotransporter SGLT1 in Xenopus oocytes is characterized by a phlorizin-sensitive leak current (in the absence of glucose) that was originally called a "Na(+) leak" and represents some 5-10% of the maximal Na(+)/glucose cotransport current. We analyzed the ionic nature of the leak current... | null | abstract | [
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [
"SGLT1",
"Xenopus",
"phlorizin",
"glucose",
"glucose",
"human",
"SGLT1",
"C292A",
"SGLT1",
"Cs(+)",
"SGLT1",
"SGLT1",
"water",
"water"
] | [
135,
144,
182,
234,
332,
418,
424,
438,
573,
1076,
1196,
1494,
1584,
1619
] | [
5,
7,
9,
7,
7,
5,
5,
5,
5,
5,
5,
5,
5,
5
] | [
"6523",
"8355",
"MESH:D010695",
"MESH:D005947",
"MESH:D005947",
"9606",
"6523",
"tmVar:c|SUB|C|292|A;HGVS:c.292C>A;VariantGroup:0;CorrespondingGene:6523;CorrespondingSpecies:9606",
"6523",
"MESH:D002586",
"6523",
"6523",
"MESH:D014867",
"MESH:D014867"
] | [
"Gene",
"Species",
"Chemical",
"Chemical",
"Chemical",
"Species",
"Gene",
"DNAMutation",
"Gene",
"Chemical",
"Gene",
"Gene",
"Chemical",
"Chemical"
] |
20338850 | 0 | Association thermodynamics and conformational stability of beta-sheet amyloid beta(17-42) oligomers: effects of E22Q (Dutch) mutation and charge neutralization. | null | title | [
1
] | [
"E22Q"
] | [
112
] | [
4
] | [
"tmVar:p|SUB|E|22|Q;HGVS:p.E22Q;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606"
] | [
"ProteinMutation"
] |
20338850 | 161 | Amyloid fibrils are associated with many neurodegenerative diseases. It was found that amyloidogenic oligomers, not mature fibrils, are neurotoxic agents related to these diseases. Molecular mechanisms of infectivity, pathways of aggregation, and molecular structure of these oligomers remain elusive. Here, we use all-a... | null | abstract | [
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [
"Amyloid",
"neurodegenerative diseases",
"neurotoxic",
"Abeta(17-42)",
"Glu(22)",
"E22Q",
"Abeta(17-42)",
"Glu(22)",
"E22Q",
"E22Q",
"Abeta(17-42)",
"Abeta(17-42)",
"Glu(22)",
"Asp",
"Lys",
"Abeta(17-42)"
] | [
161,
202,
297,
775,
835,
856,
1272,
1335,
1470,
1534,
2061,
2146,
2185,
2296,
2308,
2430
] | [
7,
26,
10,
12,
7,
4,
12,
7,
4,
4,
12,
12,
7,
3,
3,
12
] | [
"MESH:C000718787",
"MESH:D019636",
"MESH:D020258",
"351",
"-",
"tmVar:p|SUB|E|22|Q;HGVS:p.E22Q;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606",
"351",
"-",
"tmVar:p|SUB|E|22|Q;HGVS:p.E22Q;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606",
"tmVar:p|SUB|E|22|Q;HGVS:p.E2... | [
"Disease",
"Disease",
"Disease",
"Gene",
"Chemical",
"ProteinMutation",
"Gene",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Gene",
"Gene",
"Chemical",
"Chemical",
"Chemical",
"Gene"
] |
20338887 | 0 | Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. | null | title | [
3,
4,
5
] | [
"Gly307Ser",
"CD226",
"multiple autoimmune diseases"
] | [
24,
38,
81
] | [
9,
5,
28
] | [
"tmVar:p|SUB|G|307|S;HGVS:p.G307S;VariantGroup:0;CorrespondingGene:10666;RS#:763361;CorrespondingSpecies:9606;CA#:8994312",
"10666",
"MESH:D001327"
] | [
"ProteinMutation",
"Gene",
"Disease"
] |
20338887 | 111 | OBJECTIVES: Recently, a non-synonymous (Gly307Ser) variant, rs763361, in the CD226 gene was shown to be associated with multiple autoimmune diseases (ADs) in European Caucasian populations. However, shared autoimmunity with CD226 has not been evaluated in non-European populations. The aim of the present study is to ass... | null | abstract | [
37,
38,
39,
40,
41,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54,
55,
56,
57,
58,
59,
60,
61,
62,
63,
64,
65,
66,
67
] | [
"Gly307Ser",
"rs763361",
"CD226",
"multiple autoimmune diseases",
"ADs",
"CD226",
"ADs",
"rs763361",
"coeliac disease",
"CED",
"SLE",
"RA",
"type-1 diabetes",
"T1D",
"primary SS",
"pSS",
"SLE",
"rs763361",
"ADs",
"rs763361",
"CED",
"SLE",
"RA",
"SLE",
"pSS",
"SLE",
... | [
151,
171,
188,
231,
261,
335,
501,
648,
661,
678,
707,
712,
716,
733,
742,
754,
778,
825,
886,
998,
1052,
1143,
1170,
1197,
1229,
1288,
1326,
1416,
1560,
1572,
1611
] | [
9,
8,
5,
28,
3,
5,
3,
8,
15,
3,
3,
2,
15,
3,
10,
3,
3,
8,
3,
8,
3,
3,
2,
3,
3,
3,
3,
8,
8,
5,
3
] | [
"tmVar:p|SUB|G|307|S;HGVS:p.G307S;VariantGroup:0;CorrespondingGene:10666;RS#:763361;CorrespondingSpecies:9606;CA#:8994312",
"tmVar:rs763361;VariantGroup:0;CorrespondingGene:10666;RS#:763361;CorrespondingSpecies:9606",
"10666",
"MESH:D001327",
"MESH:D001327",
"10666",
"MESH:D001327",
"tmVar:rs763361;Va... | [
"ProteinMutation",
"SNP",
"Gene",
"Disease",
"Disease",
"Gene",
"Disease",
"SNP",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"SNP",
"Disease",
"SNP",
"Disease",
"Disease",
"Disease",
"Disease",
"Disease",
"Dise... |
20340133 | 79 | Increasing the conformational stability of proteins is an important goal for both basic research and industrial applications. In vitro selection has been used successfully to increase protein stability, but more often site-directed mutagenesis is used to optimize the various forces that contribute to protein stability.... | null | abstract | [
2,
3
] | [
"D79F",
"D79F"
] | [
775,
924
] | [
4,
4
] | [
"tmVar:p|SUB|D|79|F;HGVS:p.D79F;VariantGroup:0",
"tmVar:p|SUB|D|79|F;HGVS:p.D79F;VariantGroup:0"
] | [
"ProteinMutation",
"ProteinMutation"
] |
20340137 | 0 | Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. | null | title | [
3,
4,
5
] | [
"alpha-synuclein",
"p.Ala53Thr",
"Parkinson disease"
] | [
69,
99,
121
] | [
15,
10,
17
] | [
"6622",
"tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:9606;CA#:257068",
"MESH:D010300"
] | [
"Gene",
"ProteinMutation",
"Disease"
] |
20340137 | 140 | Genetic alterations in the alpha-synuclein (SNCA) gene have been implicated in Parkinson Disease (PD), including point mutations, gene multiplications, and sequence variations within the promoter. Such alterations may be involved in pathology through structural changes or overexpression of the protein leading to protei... | null | abstract | [
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43
] | [
"alpha-synuclein",
"SNCA",
"Parkinson Disease",
"PD",
"SNCA",
"SNCA",
"patient",
"p.Ala53Thr",
"PD",
"SNCA",
"patient",
"SNCA",
"patient",
"SNCA",
"SNCA",
"patient",
"p.Ala53Thr",
"SNCA",
"PD"
] | [
167,
184,
219,
238,
592,
670,
741,
766,
817,
870,
912,
1082,
1102,
1141,
1212,
1236,
1286,
1402,
1453
] | [
15,
4,
17,
2,
4,
4,
7,
10,
2,
4,
7,
4,
7,
4,
4,
7,
10,
4,
2
] | [
"6622",
"6622",
"MESH:D010300",
"MESH:D010300",
"6622",
"6622",
"9606",
"tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:9606;CA#:257068",
"MESH:D010300",
"6622",
"9606",
"6622",
"9606",
"6622",
"6622",
"9606",
"tmVar:p|SUB|A|53... | [
"Gene",
"Gene",
"Disease",
"Disease",
"Gene",
"Gene",
"Species",
"ProteinMutation",
"Disease",
"Gene",
"Species",
"Gene",
"Species",
"Gene",
"Gene",
"Species",
"ProteinMutation",
"Gene",
"Disease"
] |
20340139 | 106 | There are 35 missense mutations among 68 different mutations in the TPP1 gene, which encodes tripeptidyl peptidase I (TPPI), a lysosomal aminopeptidase associated with classic late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). To elucidate the molecular mechanisms underlying TPPI deficiency in patients carry... | null | abstract | [
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [
"TPP1",
"tripeptidyl peptidase I",
"TPPI",
"late-infantile neuronal ceroid lipofuscinosis",
"CLN2 disease",
"TPPI deficiency",
"patients",
"human",
"TPP1",
"TPPI",
"Chinese hamster ovary",
"TPPI",
"p.Gly77Arg",
"TPPI",
"p.Arg447His",
"TPPI"
] | [
174,
199,
224,
282,
329,
393,
412,
630,
636,
685,
712,
746,
997,
1234,
1360,
1539
] | [
4,
23,
4,
45,
12,
15,
8,
5,
4,
4,
21,
4,
10,
4,
11,
4
] | [
"1200",
"1200",
"1200",
"MESH:D009472",
"MESH:C566857",
"MESH:D006969",
"9606",
"9606",
"1200",
"1200",
"CVCL:0213",
"1200",
"tmVar:p|SUB|G|77|R;HGVS:p.G77R;VariantGroup:0;CorrespondingGene:1200;RS#:121908195;CorrespondingSpecies:9606;CA#:266187",
"1200",
"tmVar:p|SUB|R|447|H;HGVS:p.R447... | [
"Gene",
"Gene",
"Gene",
"Disease",
"Disease",
"Disease",
"Species",
"Species",
"Gene",
"Gene",
"CellLine",
"Gene",
"ProteinMutation",
"Gene",
"ProteinMutation",
"Gene"
] |
20349493 | 82 | The two homologous proteins ribonuclease A and onconase fold through conserved initial contacts but differ significantly in their thermodynamic stability. A disulfide bond is located in the folding initiation site of onconase (the C-terminal part of the protein molecule) that is missing in ribonuclease A, whereas the o... | null | abstract | [
9,
10,
11,
12,
13,
14,
15
] | [
"disulfide",
"disulfide",
"disulfide",
"C104",
"C87A",
"C104A",
"disulfide"
] | [
239,
413,
520,
540,
650,
655,
1494
] | [
9,
9,
9,
4,
4,
5,
9
] | [
"MESH:D004220",
"MESH:D004220",
"MESH:D004220",
"tmVar:c|Allele|C|104;VariantGroup:0",
"tmVar:c|SUB|C|87|A;HGVS:c.87C>A;VariantGroup:1",
"tmVar:c|SUB|C|104|A;HGVS:c.104C>A;VariantGroup:0",
"MESH:D004220"
] | [
"Chemical",
"Chemical",
"Chemical",
"DNAMutation",
"DNAMutation",
"DNAMutation",
"Chemical"
] |
20349607 | 111 | CD52 is a small glycopeptide leukocyte antigen present on selected subpopulations of human cells. From the clinical point of view this protein is an important target for therapeutic interventions aimed at leukocyte depletion in hematological malignancies and post-transplant immunosuppression. Recently, two variants of ... | null | abstract | [
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [
"CD52",
"human",
"hematological malignancies",
"CD52",
"rs1071849",
"A119G",
"Asn40Ser",
"rs17645",
"A123G",
"CD52",
"CD52"
] | [
111,
196,
339,
431,
437,
448,
455,
469,
478,
647,
766
] | [
4,
5,
26,
4,
9,
5,
8,
7,
5,
4,
4
] | [
"1043",
"9606",
"MESH:D019337",
"1043",
"tmVar:rs1071849;VariantGroup:0;CorrespondingGene:1043;RS#:1071849;CorrespondingSpecies:9606",
"tmVar:c|SUB|A|119|G;HGVS:c.119A>G;VariantGroup:0;CorrespondingGene:1043;RS#:1071849;CorrespondingSpecies:9606;CA#:703354",
"tmVar:p|SUB|N|40|S;HGVS:p.N40S;VariantGroup:... | [
"Gene",
"Species",
"Disease",
"Gene",
"SNP",
"DNAMutation",
"ProteinMutation",
"SNP",
"DNAMutation",
"Gene",
"Gene"
] |
20349940 | 89 | In addition to the four known stylissamides, A (1), B (2), C, and D, two new cyclic heptapeptides, stylissamides E (3) and F (4), were isolated from the Caribbean sponge Stylissa caribica. The structures of 3 and 4 were elucidated from a combination of mass spectrometric and NMR spectroscopic data as cyclo-(cis-Pro(1)-... | null | abstract | [
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [
"stylissamides",
"A (1), B (2), C, and D",
"cyclic heptapeptides",
"stylissamides E (3) and F (4)",
"sponge",
"Stylissa caribica",
"Pro(1)-Tyr",
"Pro(3)-Ala",
"Ile(5)-Gln",
"stylissamide E",
"Pro(2)-Phe",
"Pro(5)-Arg",
"stylissamide F (4)"
] | [
119,
134,
166,
188,
252,
259,
402,
422,
436,
462,
509,
536,
562
] | [
13,
22,
20,
29,
6,
17,
10,
10,
10,
14,
10,
10,
18
] | [
"-",
"-",
"-",
"-",
null,
null,
"tmVar:p|SUB|P||Y;VariantGroup:4",
"tmVar:p|SUB|P||A;VariantGroup:2",
"tmVar:p|SUB|I||Q;VariantGroup:1",
"MESH:C549728",
"tmVar:p|SUB|P|2|F;HGVS:p.P2F;VariantGroup:0",
"tmVar:p|SUB|P||R;VariantGroup:3",
"-"
] | [
"Chemical",
"Chemical",
"Chemical",
"Chemical",
"Species",
"Species",
"ProteinMutation",
"ProteinMutation",
"ProteinMutation",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Chemical"
] |
20349984 | 150 | The molecular pathway of enrofloxacin, a fluoroquinolone antibiotic, through the outer membrane channel OmpF of Escherichia coli is investigated. High-resolution ion current fluctuation analysis reveals a strong affinity for enrofloxacin to OmpF, the highest value ever recorded for an antibiotic-channel interaction. A ... | null | abstract | [
11,
12,
13,
14,
15,
16,
17
] | [
"enrofloxacin",
"fluoroquinolone",
"Escherichia coli",
"enrofloxacin",
"aspartic acid at the 113 position",
"D113N",
"enrofloxacin"
] | [
175,
191,
262,
375,
536,
587,
798
] | [
12,
15,
16,
12,
33,
5,
12
] | [
"MESH:D000077422",
"MESH:D024841",
"562",
"MESH:D000077422",
"tmVar:p|Allele|D|113;VariantGroup:0",
"tmVar:p|SUB|D|113|N;HGVS:p.D113N;VariantGroup:0",
"MESH:D000077422"
] | [
"Chemical",
"Chemical",
"Species",
"Chemical",
"ProteinMutation",
"ProteinMutation",
"Chemical"
] |
20350135 | 98 | AIMS: Genetic contributions to nicotine dependence have been demonstrated repeatedly, but the relevance of individual polymorphisms for smoking cessation remains controversial. MATERIALS & METHODS: We examined genotypes at two dopamine-related loci, DRD2/ANKK1 (rs1800497) and DBH (rs77905), in 577 heavy smokers partici... | null | abstract | [
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [
"nicotine dependence",
"dopamine",
"DRD2",
"ANKK1",
"rs1800497",
"DBH",
"rs77905",
"DRD2",
"ANKK1",
"DBH",
"bupropion",
"buproprion",
"DRD2",
"ANKK1",
"DRD2",
"ANKK1"
] | [
129,
325,
348,
353,
360,
375,
380,
568,
573,
724,
765,
914,
1030,
1035,
1198,
1203
] | [
19,
8,
4,
5,
9,
3,
7,
4,
5,
3,
9,
10,
4,
5,
4,
5
] | [
"MESH:D014029",
"MESH:D004298",
"1813",
"255239",
"tmVar:rs1800497;VariantGroup:1;CorrespondingGene:255239;RS#:1800497;CorrespondingSpecies:9606",
"1621",
"tmVar:rs77905;VariantGroup:0;CorrespondingGene:1621;RS#:77905;CorrespondingSpecies:9606",
"1813",
"255239",
"1621",
"MESH:D016642",
"-",
... | [
"Disease",
"Chemical",
"Gene",
"Gene",
"SNP",
"Gene",
"SNP",
"Gene",
"Gene",
"Gene",
"Chemical",
"Chemical",
"Gene",
"Gene",
"Gene",
"Gene"
] |
20350212 | 137 | AIM: The t(14;18)(q32;q21) chromosomal translocation induces BCL2 protein expression in most follicular lymphomas. However, a small number of cases lack BCL2 expression despite carrying the t(14;18)(q32;q21) translocation. This study aims to explore the mechanism accounting for the lack of BCL2 protein expression when ... | null | abstract | [
46,
47,
48,
49,
50,
51,
52,
53,
54,
55,
56,
57,
58,
59,
60,
61,
62,
63,
64,
65,
66,
67,
68,
69,
70,
71,
72,
73,
74,
75,
76,
77,
78,
79,
80,
81,
82,
83,
84,
85
] | [
"BCL2",
"follicular lymphomas",
"BCL2",
"BCL2",
"BCL2",
"FL18",
"Karpas-422",
"SU-DHL-4",
"SU-DHL-6",
"BCL2",
"BCL2",
"FL18",
"Karpas-422",
"SU-DHL-4",
"SU-DHL-6",
"FL18",
"Karpas-422",
"SU-DHL-4",
"BCL2",
"BCL2",
"BCL2",
"SU-DHL-6",
"BCL2",
"BCL2",
"BCL2",
"SU-DHL-... | [
198,
230,
290,
428,
505,
557,
563,
575,
588,
828,
879,
901,
907,
919,
932,
965,
971,
987,
1001,
1037,
1075,
1108,
1142,
1157,
1275,
1310,
1383,
1430,
1527,
1617,
1663,
1681,
1772,
1778,
1798,
1804,
1836,
1933,
1978,
2105
] | [
4,
20,
4,
4,
4,
4,
10,
8,
8,
4,
4,
4,
10,
8,
8,
4,
10,
8,
4,
4,
4,
8,
4,
4,
4,
8,
4,
4,
4,
8,
8,
4,
4,
4,
4,
5,
4,
4,
4,
4
] | [
"596",
"MESH:D008224",
"596",
"596",
"596",
"CVCL:8093",
"CVCL:1325",
"CVCL:0539",
"CVCL:2206",
"596",
"596",
"CVCL:8093",
"CVCL:1325",
"CVCL:0539",
"CVCL:2206",
"CVCL:8093",
"CVCL:1325",
"CVCL:0539",
"596",
"596",
"596",
"CVCL:2206",
"596",
"596",
"596",
"CVCL:2206... | [
"Gene",
"Disease",
"Gene",
"Gene",
"Gene",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"Gene",
"Gene",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"CellLine",
"Gene",
"Gene",
"Gene",
"CellLine",
"Gene",
"Gene",
"Gene",
"CellLine",
"... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 51